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ABSTRACT
The inhibitors of histone deacetylases (HDACs) have shown promising neuroprotective
and neuroactive properties. A set of pan- and isoform-specific HDAC inhibitors were evaluated
for neurotrophic activity on Neuroscreen-1 (NS-1) cells, a subclone of PC-12 (rat
pheochromocytoma) cells.
The HDAC inhibitors were tested alone and in combination with nerve growth factor
(NGF). An in vitro method has been standardized that measures neurite outgrowth along with
cytotoxicity of test compounds in a single assay. The neurotrophin signaling pathways were
interrogated with selective inhibitors of MEK1/2 (PD98059/U0126) PI3K (LY294002) and TrkA
(GW441756) and phosphorylation of target kinases. Associated factors namely, acetylation of
histones (H3/H4) and α-tubulin, role of cAMP, and cell- cycle analysis with flowcytometry were
also studied.
Vorinostat, a pan HDAC inhibitor, independently induced significant neurite outgrowth in
NS-1 cells, similar to that of NGF. The inhibitors of MEK1/2 & PI3K attenuated the NGF and
vorinostat mediated neurite outgrowth. Vorinostat induced phosphorylation of ERK1/2 was
abolished in presence of U0126. Both, vorinostat-mediated neurite outgrowth and activation of
ERK were attenuated in presence of the TrkA inhibitor, GW441756, indicating the role of
activation of upstream neurotrophin receptor. Vorinostat produced hyperacetylation of α-tubulin
and histones H3/H4. However, SQ22536 (the adenylate cyclase inhibitor) further stimulated
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neurotrophic action of vorinostat. Trichostatin A (TSA), belinostat and additional pan-HDAC
inhibitors, showed variable effects. TSA was ineffective, while belinostat attenuated neurotrophic
action of NGF. Belinostat though induced hyperacetylation of H3 & H4 but failed to produce
acetylation of α-tubulin. PCI-34051, the HDAC 8 inhibitor, produced marginal neurotrophic action
but did not produce hyperacetylation of H3/H4 and α-tubulin. Tubastatin-A, the HDAC 6
inhibitor, although produced hyperacetylation of α-tubulin but did not show any neurotrophic
action. Tenovin-1, a sirtuin inhibitor, attenuated neurotrophic action of NGF and did not produce
hyperacetylation of H3/H4.
These results suggest promising neurotrophic action of vorinostat via activation of MEK1/2
& PI3K pathways involving activation of upstream TrkA, a neurotrophin receptor. Bioactive small
molecules with neurotrophic and neuritogenic actions, like vorinostat identified in present studies,
hold great promise as therapeutic agents for treatment of neurodegenerative diseases and neuronal
injuries by virtue of their ability to stimulate neuritic outgrowth.
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CHAPTER 1
INTRODUCTION
1.1 Acetylome: Protein Lysine acetylation and Deacetylation functions
Post-translational modifications are prominent, important and necessary processes for
transformation of raw protein molecules into functional entities. The acetylation of proteins at
specific lysine residues by acetyltransferases enzymes has emerged as a biologically related
regulatory modification like phosphorylation (Kouzarides, 2000). The acetyl transferases catalyze
transfer of acetyl group from acetyl Co-A to the α-amino group of the amino terminal residues or
to the ε-group of specific lysine residue (Allis et. al., 2007). Deacetylation, the reverse reaction of
removal of acetyl group from acetyl lysine residues, is accomplished by another group of enzymes
named deacetylases. Lysine protein acetylation was first identified in histones many years ago so
many KATs and KDACs are often referred to as histone acetyl transferases (HATs) and
deacetylases (HDACs) (Yang and Seto, 2008). A variety of proteins are known to be acetylated
including histones and non-histone proteins. Lysine acetylation is known to occur in over 80
transcription factors, a large number of nuclear regulators and several cytoplasmic proteins
(Glozak et. al, 2005). Post translational modifications of these proteins play a very significant role
in variety of cellular and biological process. Some of the prominent cellular process controlled by
the lysine protein acetylation/deacetylation include chromatin modification and transcription, gene
silencing, cellular differentiation, cell cycle progression, DNA replication, DNA repair
(Chaudhary et. al., 2009) apoptosis (Lebel et. al., 2000). Most of the intermediate enzymes in the
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metabolic pathways are acetylated. Acetylation of these enzymes regulates cellular metabolism by
directly affecting their stability and functions (Zhou et. al., 2010). Lysine protein acetylation also
plays important role in p53 functions and interaction and stabilization of microtubules.
1.2 Histone acetylation and deacetylation
Chromatin is the state in which DNA is packaged within the nucleus of the cell. The
fundamental unit of the chromatin is the nucleosome, which is composed of octamers of the four
core histones (H3, H4, H2A, and H2B). Each histone octamer is wrapped around with 147 base
pairs of DNA (Kourzadias, 2007). Chromatin is a very active structure as it responds to various
signals and controls functions of the DNA. Histone modifications are the main components that
regulate DNA functions. Histones undergo a variety of post-translational modifications namely
acetylation, phosphorylation, methylation and ubiquitination (Bannister and Kouzadias, 2011).
Histone acetylation is one of the important post-translational modifications that regulate gene
expression. Acetylation and deacetylation is a highly dynamic process and is catalyzed by interplay
of two opposing enzymes histone acetyl transferases (HATs) and histone deacetylases (HDACs)
(Figure 1.1). HATs catalyze the addition of acetyl group at the lysine side chain of histones while
HDACs catalyze removal of acetyl group from epsilon amino group of the lysine side chain of
histone. Acetylation of histone tails neutralizes their positive charge resulting into loosening of
histones and the associated DNA, thereby providing the relaxed chromatin structure that is
accessible to the transcription factors and thus promoting transcriptional activation (Parthun 2007).
Conversely, deacetylation of histone favors chromatin compaction. Generally, hyperacetylation
of histone is associated with transcriptional activation, whereas hypoacetylation is associated with
transcriptional repression (Hsieh et. al., 2004).
2

Adopted from Chuang et.al., 2009

Figure 1.1. Role of histone acetylation and deacetylation in process of transcription regulation.
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1.3. HAT and HDACS
1.3.1. Histone Acetyl Transferases (HATs)
In humans, there are about 30 known HATs, which have been grouped into five families
based on structural and functional similarity of their catalytic domains. Gcn5 related N-Acetyl
transferases (GNATs) have derived their name from bearing similarity to yeast Gcn5 (general
control nonderepressible-5) enzymes. This group includes HAT Gcn5 and its relative and some
distantly related HATs like Hat1, Elp3 and Hpa2. GNATs have four conserved motif (A-D) within
the catalytic domain HAT domain. Motif A is the most highly conserved and contains an Arg/GlnX-X-Gly-X-Gly/Ala sequence that is important for acetyl-CoA recognition and binding (Roth et.
al., 2001). The chromodomain or bromodomain in GNATs are involved in their binding with
methylated and acetylated lysine respectively (Neuwald and Landsman, 1997). The MYST
families of HATs are originally named for their founding members MOZ, Ybf2, Sas2, and Tip60.
The MYST HATs plays a very important role in posttranslational modification of histones. MYST
HATs have a characteristic domain that contains acetyl CoA binding motif and a zinc finger motif
(Avvakumov and Cote, 2007). The other families are global co-activators nuclear receptor
coactivators and divers. The global co-activator includes p300 and CREB binding Protein. Nuclear
receptor co -activators includes steroid receptor co-activator (SRC-1), ACTR, and (Transcriptional
intermediary factors) TIF2. The divers include TAFII 250 (TATA binding protein (TBP) associated factor) and P160 (Sadoul et. al., 2011).
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1.3.2. Histone Deacetylases (HDACs)
Histone deacetylases are enzymes that remove acetyl group from histones leading to
compact chromatin structures. HDACs are part of co-repressor complexes. The HDACs have been
shown to control many biological processes such as cellular proliferation, differentiation and
development by binding to many transcription factors and transcription co-regulators (Haberland
et. al., 2009).
To date ,18 mammalian HDACs have been identified and divided into four major classes
based upon their homology to yeast histone deacetylases (Figure 1.2) (de Ruijter et.al., 2003)
HDACs 1, 2, 3 and 8 are grouped in Class I based on their homology to yeast transcriptional
regulator, reduced potassium deficiency 3 (Rpd3). The class I HDACs are predominantly localized
in the nucleus. HDACs 1, 2 and 3 are expressed in the nucleus and have been shown to be involved
in cell proliferation and death (Weich et. al., 2009). HDAC 8 is found to be expressed in smooth
muscle where it is found to play important role in muscle contractility. The class II deacetylases
share homology with yeast Histone Deacetylase 1 (HD1) proteins and are further grouped into
class IIa and Class IIb. The Class IIa includes HDACs 4, 5, 7 and 9, while Class IIb includes
HDAC6 and 10. The classes II HDACs have been found to shuttle between the nucleus and
cytoplasm and seem to have a role in the tissue specific developmental activities (Bjerling et. al.,
2002). Class IV includes only one atypical HDAC isoform 11. It is highly expressed in the
kidneys, testis and brain. HDAC11 is known to deacetylate histones as well as some non-histone
proteins namely, a nuclear hormone receptor, transcription factors and cytoskeletal elements
(Haberland et. al., 2009, Yang and Seto, 2008). Class I, II and IV HDACs are zinc-dependent and
are also called as classical HDACs. Class III HDACs, commonly known as sirtuins (SIRT 1-7),
5

are structurally and functionally different from the classical HDACs. These NAD-dependent
HDACs are similar to yeast SIR 2 (Silent Information Regulators 2) (Weich et. al., 2009). Sirtuins
are involved in regulation of metabolism, stress response and aging (Michan and D, 2007).

6

Classification of HDACs and their localization

Figure 1.2. Classification of Histone Deacetylases (HDACs) and their cellular localization.
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1.4. HDAC Inhibitors (HDACi)
HDACi are small molecule natural or synthetic inhibitors of HDAC enzymes. These
compounds vary in structures, selectivity and biological activities. HDACi pharmacophore is
typically consisting of a metal-binding moiety or functional group, a capping group and a linker.
The metal binding group coordinates to the catalytic metal atom within the HDAC active site. The
capping group interacts with the residues at the entrance of the active site and the linker is
structurally related to the carbon chain present in the acetyl-lysine substrate. Main function of the
linker is to appropriately position the metal-binding moiety and capping group for interactions
with the HDAC active site (Finnin et.al., 1999) (Figure1.3.A). HDACi have been grouped into
four major classes, based on chemical nature of the inhibitor. (A) Hydroxamates (eg, Vorinostat
(SAHA), Belinostat (PXD101), Panobinostat (LBH589) and Trichostatin A. The hydroxamate
HDACi are non-specific and show activity against class I and class II HDACs. Trichostatin A and
vorinostat are pan-HDAC inhibitors of all zinc-dependent HDACs and are reported to cross blood
brain barrier. (B) The cyclic peptide HDACi includes depsipeptides and trapoxin. In in vitro
assays, cyclic peptides are active at nanomolar concentrations (Marks, 2010) (C) The benzamide
HDACi include entinostat (MS-275) and mocetinostat and (D) Short chain fatty acids HDACi
include sodium butyrate and valproic acid (Marks, 2010) (Table1.3.B). The short chain fatty acids
HDACi could also cross blood brain barrier, however they are relatively moderate HDACi (Bulter
and Bates, 2006). The majority of HDACi available are non-specific inhibitors of all the HDAC
isoforms. These are generally referred as pan-HDAC inhibitors. TSA and vorinostat are example
of canonical pan-HDAC inhibitors that inhibit HDACs 1-9 with equivalent potency. Selective
HDACi can be classified into either class-specific (inhibiting several isoforms within a single
class) or isoform-specific HDAC inhibitor (selectively inhibiting a specific HDAC isoform).
8

Selective HDAC inhibitors are important for determining the molecular mechanism of functions
of a specific HDAC isoform. Recently, significant attempts have been made towards development
of selective HDAC inhibitors. Tubacin, an HDAC inhibitor, selectively targets the HDAC6 and
deacetylation of α-tubulin (Haggarty et. al., 2003). Romidepsin (FK-228) is a cyclic tetrapeptide,
which potentially inhibits HDAC 1 and 2 (Itoh et. al., 2008). Apicidin, another cyclic tetrapeptide
is a highly potent inhibitor of HDAC2 & 3 (Khan et. al., 2008) MS-275, a synthetic benzamide
derivative, preferentially inhibits HDAC1 as compared to HDAC 2, 3 and 9. MS-275 exhibits little
to no activity against HDAC4, 6, 7 and 9 (Khan et. al., 2008). Suramin inhibits human NAD+
dependent class III SIRT 1 and SIRT 2 activity (Trapp et. al., 2007).

Basic structure of HDAC inhibitors
A

Figure 1.3. (A) Basic structure of HDAC inhibitors.
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B

CLASSIFICATION OF HDAC INHIBITORS

Class
Compounds
Hydroxamates TSA
(Trichostatin A)

Cyclic
peptides

Entinostat

Benzamides

Trapoxin B

Short chain
fatty acids

Valproic acid

Structure

Figure 1.3. (B) Classification of HDAC inhibitors based on their chemical structure.
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1.5. HDACi as potential therapeutic agents for treatment of neurological disorders
Inhibition of HDAC activity with HDACi has attracted significant therapeutic attention.
Earlier interests were mainly focused on development of HDACi as anticancer agents (Kazantsev
and Thompson, 2008).

HDAC inhibitors, including butyrate, trichostatin A (TSA),

suberoylanilide hydroxamic acid (SAHA), MS-275, and others, inhibit growth and induce
differentiation in various cell culture models of cancer, including leukemia. SAHA (vorinostat,
Zolinza) is the first HDACi approved by the FDA for cutaneous T- cell leukemia. A number of
HDACi are currently in Phase I and Phase II clinical trials as cancer therapeutics (Marks and Xu,
2009). More recently, the therapeutic interests in HDACi have broadened to non-malignant
conditions affecting the nervous system (Kazantsev and Thompson, 2008). Targeting HDACs
with HDACi might be useful for treatment of neurological disorders such as amyotrophic lateral
sclerosis, seizure disorders, Alzheimer's disease, Rubinstein-Taybi syndrome, spinal muscular
atrophy, Rett syndrome, stroke, Fragile X syndrome, and Huntington's disease (Chuang et. al.,
2009). The HDACi also seem promising for therapy related to several psychiatric disorders,
including schizophrenia, depression, drug addiction, and anxiety disorders (Guidotti et. al., 2009).
The levels and activities of HATs and HDACs are finely balanced in neuronal cells under normal
conditions (Saha et. al., 2006). In neurodegenerative disease, the histone acetylation homeostasis
is greatly impaired, shifting towards hypoacetylation (Saha et. al., 2006).

The histone

hyperacetylation produced by direct inhibition of HDACs leads to neuroprotective actions.
Besides, inhibition of HDACs and histone hyperacetylation, the neuroprotective effect of HDACi
may also involve multiple mechanisms of action, including activation of the extracellular signal
regulated kinase pathway (Hao et. al., 2004), the inhibition of pro-apoptotic factors (Kim et. al.,
2007) or microglial–mediated inflammation (Peng et. al., 2005), as reported earlier for valproic
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acid. Therefore, HDACs represent attractive molecular targets for the treatment of several
neurological and psychiatric diseases. In preclinical treatment models, the HDACi have exhibited
neuroprotective effects and stimulation of neurogenesis in traumatic brain injury and ischemia
(Kim et. al., 2009), restoration of learning and memory in traumatic brain injury in
neurodegenerative mice (Das et. al., 2009), enhanced neuronal differentiation and synaptic
plasticity (Vecsey et. al., 2007) and exerted antidepressant-like effects (Schroeder et. al., 2007).
Vorinostat significantly reduced IFN- λ induced neurotoxicity of human astrocytes (Hashioka et.
al., 2012).
1.5.1. Spinal Muscular Atrophy
In spinal muscular atrophy (SMA) models, SAHA has been shown to improve motor
abilities, by improving the number of motor neurons in the mice. SAHA treatment was shown to
improve weight loss in SMA mice (Riessland et. al., 2010). In another study, daily injection of
TSA in SMA mice after the onset of disease lead to HDAC inhibition activated SMN2 gene
expression and improved survival and motor pathology and attenuated weight loss (Avila et. al.,
2007).
1.5.2. Huntington Disease
HDAC inhibitors treatment in R6/2 Huntington disease (HD) mouse model showed
improvement in Rotarod performance, which indicates improvement in motor impairment. SAHA
has been shown to cross the blood brain barrier and increase histone acetylation in the brain
(Hockly et. al., 2003). Ferrante et. al., (2003) reported that sodium butyrate treatment attenuated
neurodegenerative phenotype and improved survival in R6/2 HD models. Treatment with SAHA
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and sodium butyrate has been shown to slow photoreceptor neurodegeneration and improves
lethality in a Drosophila model of HD (Steffan et. al., 2001). A defect in microtubule transport is
also attributed to the neuronal toxicity observed in HD. Vorinostat and TSA have been shown to
increase vesicular transport of BDNF by inhibiting HDAC6 and thereby increasing the acetylation
of α-tubulin at Lys 40. Acetylation of α-tubulin at Lys 40 influences the binding and motility of
kinesin-1 (Dompirre et. al., 2007).
1.5.3. Parkinson’s Disease
Parkinson’s disease is a neurodegenerative disorder characterized by loss of dopaminergic
neurons in substantia niagra of the brain. In a study with a mouse model of PD treated with
dopaminergic toxin MPTP, administration of HDAC inhibitor phenyl butyrate significantly
attenuated the depletion of dopamine and loss of tyrosine hydroxylase, the dopamine biosynthetic
enzyme, positive neurons (Gardian et. al., 2004). Mutations in presynaptic α-synuclein are
associated with familial forms of PD (Gasser, 2001). The α-synuclein mediates neurotoxicity in
the nucleus. Targeting of α-synuclein to the nucleus promotes toxicity, whereas cytoplasmic
sequestration is protective in both cell culture and transgenic Drosophila (Kontopoulos et. al.,
2006). Toxicity of α-synuclein could be rescued by administration of HDAC inhibitors such as
vorinostat and sodium butyrate in both cell culture and transgenic flies. It was found that treatment
with the HDACi lead to reduced neuronal death in response to α-synuclein (Kontopoulos et. al.,
2006).
TSA treatment resulted in decreased survival and increased apoptosis in dopaminergic
neuronal cells like N27, MN9D and human SH-SY5Y cells (Wang et. al., 2009). This finding
suggested that the effect of HDAC inhibitors might be complex. In some instances the HDAC
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inhibitors could play a role in pathogenesis of the neurodegenerative disease while in others these
may act as potential therapeutics for neurodegenerative disease. These contrasting effects of
HDAC inhibitor may be attributed to varying epigenetic status, cell type and tissue specificity.
HDAC inhibitors such as TSA and VPA, the pan-HDAC inhibitors of class I and class II are nonspecific. Plausibly, this non-specificity might contribute to contradictory effects observed in
different cell types (Wang et. al., 2009).
Most of the earlier reports on HDACi were focused on their anticancer, antiproliferative
and antiapoptotic properties. Hyperacetylation was associated with an increase in expression of
pro-apoptotic genes such as Bax and P21. However, an increase in acetylation also promoted
expression of anti-apoptotic or pro-survival genes like Bcl-2 and growth factors, which leads to
protective effects in other cell types. This might be one mechanism by which HDAC inhibitors
seem to be protective in neurons and deadly in cancerous cell (Saha et. al., 2006).
1.5.4. Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is an adult onset neurodegenerative disease
characterized by progressive loss of motor neurons in the brain, brain stem and spinal cord
resulting in generalized weakness, muscle atrophy and mortality (Rowland and Shneider, 2001).
Familial form of ALS are due to gain of functional mutation in the gene encoding Cu/Zn
superoxide dismutase1 (SOD1) an antioxidant enzyme (Rosen et.al., 1993). As transcriptional
regulation may be involved in the pathophysiology of ALS, role of HDAC inhibitors have been
studied in transgenic ALS mouse models. Studies done by Ryu et. al., (2005) have shown that
administration of 4-phenylbutryrate starting before or shortly after the onset of symptoms resulted
in extended survival, improved pathological phenotype and reduction in clinical impairment. VPA
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injection in G86R SOD1 mutant mice significantly attenuated the death of motor neurons,
maintained normal level of acetylation of histones and restored the loss of HAT CBP (Rouax et.
al., 2007). Co- treatment of 4-phenylbutyrate and AEOL10150 a catalytic antioxidant to ALS
mice had a cumulative effect on survival time and there was reduction in the markers of oxidative
damage in the lumbar spinal cord (Petri et. al., 2006).
1.5.5. Alzheimer’s Disease
Alzheimer’s Disease (AD) is characterized by progressive memory loss and personality
changes eventually leading to dementia (Burns & Iliffe, 2009). Accumulation of extracellular βamyloid (Aβ) and neurofibrillary tangles resulting from hyperphosphorylation of Tau protein are
the neuropathological hallmark of AD. Daily administration of 4-phenylbutyrate in Tg2576 AD
model reversed spatial memory deficit by normalizing Tau hyperphosphorylation in the
hippocampus. However, the Aβ levels were not affected due to treatment with 4-phenylbutyrate
(Ricobaraza et. al., 2009). In another study, daily injection of low doses of valproic acid in Tg2576
AD mice at early onset of 27 months, significantly reduced Aβ plaque number and improved
memory deficit. The mechanism of Aβ plaque reduction by valproic acid was due to inhibition of
GSK-3β-mediated γ-secretase cleavage of APP (Qing et. al., 2008). Treatment of 3xTg-AD mice
with a class III HDAC inhibitor, nicotinamide, prohibited memory impairment and reduced Tau
pathology without affecting Aβ production. There was also a chronic but low level of increase in
endogenous p25, which was associated with improved learning and memory (Green et. al., 2008).
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1.5.6. Multiple Sclerosis
Multiple Sclerosis (MS) is a devastating autoimmune disorder of CNS. Recent studies
have pointed towards the potential therapeutic role of HDACi in this disorder. A study by Camelo
et. al., (2005) on experimental autoimmune encephalomyelitis (EAE), a model of multiple
sclerosis, demonstrated that neuropathology of mice with EAE was ameliorated by TSA treatment.
The animals treated with TSA showed reduced spinal cord inflammatory infiltrates, demyelination
and axonal loss. Interestingly, TSA treatment also increased the number of motor neurons in the
ventral horn, suggesting the potential application of TSA in neuroprotection. TSA treatment
increased expression of neuroprotective proteins such as estrogen receptor-α, insulin growth
factor-2 (IGF-2), glutamate transporter EAAT2 and glutathione peroxidase, and decreased the
expression of pro-apoptotic Bax, Bid, caspase-2 and apoptosis-inducing factor (Camelo et.al.,
2005).
Axonal damage is also an important cause of neurodegeneration, where histone
deacetylases play an important role. A study with a specific wallerian degeneration mouse (WID)
shows delayed wallerian degeneration due to increase in activity of NAD+ dependent histone
deacetylase SIRT 1. These mice had an increased expression of the enzyme that produces NAD+
leading to increased SIRT 1 activity. Neuronal damage due to progressive degeneration after
axonal transfection in this specific mouse was inhibited (Arkai et. al., 2004).
1.6. Neuroprotective effects of HDACi
VPA has been shown to reduce the retinal neuronal death by optic nerve crush (ONC).
VPA up regulated levels of Bcl-2, BDNF and TrkB in the retina post-injury (Zhang et. al., 2012).
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VPA and Sodium Butyrate (SB) treatment caused hyperacetylation of histone H3K14, attenuated
histone H3K9 hypermethylation in the BDNF promoter and promoted transcriptional activity.
These results suggest that VPA seemed to protect retinal ganglion cells (RGC) from ONC by
inhibiting neuronal apoptosis, presumably, via the activation of BDNF-TrkB signaling and HDAC
inhibition (Zhang et. al., 2012).
BDNF gene expression has been associated with mood-stabilizing effects in the bipolar
disorder (BD). BDNF plays important role in promoting neuronal survival and synaptic plasticity
and has been widely studied as a biomarker of illness activity in BD (Kuipers et. al., 2006). Laura
et. al., (2014) examined repeated exposure of D-amphetamine (AMPH) in a bipolar animal model
and also investigated effect of sodium butyrate. They found that repeated AMPH administration
increased the HDAC activity in the prefrontal cortex (PFC) without altering BDNF protein or
mRNA levels. While, administration of sodium butyrate partially reversed the HDAC activity.
HDACi have shown potential for therapeutic application for treatment of neurodegenerative and
psychiatric disease owing to their neuroprotective and memory enhancing properties and increased
expression of BDNF. Koppel and Timmusk, (2013) have compared the effect of class I/IIb HDAC
inhibitor SAHA, a class I selective HDAC inhibitor MS-275 and class II selective inhibitor on
MC1568 and a HDAC6 selective inhibitor Tubacin on BDNF mRNA expression in rat primary
neurons. They also found that inhibition of class II HDACs lead to rapid up -regulation of BDNF
mRNA levels, whereas class I HDAC inhibition created a distinctly delayed BDNF induction.
Their finding suggests that class II HDAC inhibitors play important part in regulating transcription
of BDNF and may have potential application for treatment of neurological disorders. Hasan et.
al., (2013) investigated the role of HDAC inhibitors in neuroprotection after ischemia. Their study
demonstrated that VPA and TSA treatment after oxygen and glucose deprivation led to re17

oxygenation in rat cortical neurons, promoted neuronal regeneration and neuronal protection
through up-regulation of BDNF expression. There was also a significant increase in three synaptic
markers namely PSD95, GAP 43 and synaptophysin in VPA and TSA treated rat cortical neurons.
Chen et. al., (2006) have shown that VPA promoted dopaminergic neuron in midbrain neuron/glial
culture by stimulating the release of neurotrophins like BDNF and GDNF. VPA pretreatment was
also demonstrated to protect midbrain dopaminergic (DA) neurons from LPS or 1-methyl-4phenylpyridinium (MPP+)-induced neurotoxicity. LPS treatment reduced the uptake capacity of
DA by 45% and this reduction was strongly blocked by VPA pretreatment in a dose-dependent
manner. Similarly treatment with MPP+ also reduced DA uptake by 70% and VPA significantly
reduced the degeneration of DA neurons by MPP+ toxicity.
A recent study by Lu et.al., (2013) with LB-205 (pan HDAC inhibitor) in acute traumatic
brain injury rat model showed that LB-205 treatment increased the survival of central nervous
system (CNS) cells after the injury by virtue of preservation of NGF expression and activation of
tyrosine kinase A receptor (TrKA) pathway. The neuroprotective mechanism of HDACi was
linked with upregulation of expression of NGF, activation of TrkA phosphorylation, phosphoprotein kinase B (p-AKT), NFκB and B-cell lymphoma 2 (Bcl-2) cell survival factors, while the
expression of p75 neurotrophin receptor (NTR), phospho-JNK, and Bcl-2-associated X protein
apoptosis factors were down-regulated. Wu et. al., (2013) studied the effect of VPA, TSA, 4phenyl butyric acid (4-PBA) and nicotinamide in astrocyte and dopamine neuron glial culture.
TSA and VPA increased the GDNF and BDNF transcripts in astrocytes. The neurotrophin
transcript levels were increased due to increase in GDNF promoter activity leading to elevation in
level of H3 acetylation. VPA, TSA, 4-PBA and nicotinamide protected dopamine neuron/glial
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culture from MPTP and LPS toxicity. Both 4-PBA and nicotinamide decreased the release of
TNF-α and cell survivability in microglial culture stimulated with LPS (Wu et. al., 2013).
Treatment of SH-SY 5Y cells with VPA, stimulated neurite outgrowth and cell survival by
activating ERK pathway. VPA treatment enhanced norepinephrine uptake and also induced
expression of GAP-43 and Bcl-2, the genes controlled by ERK pathway (Yuan et. al., 2001). VPA
have been shown to prolong the life span of cultured cortical neurons and promote neuronal growth
(Hao et. al., 2004). In vivo effects have also shown HDACi to be neuroprotective in chronic
neurodegenerative diseases (Siebzehnrubl et. al., 2007). Increased acetylation of histones and the
transcription factors in neurons have been shown to protect from apoptosis in animal models of
neurodegeneration and promote neuronal differentiation (Siebzehnrubl et. al., 2007). TSA and
VPA have been shown to promote differentiation of hippocampal neural progenitor cells (Hsieh
et. al., 2004). HDACi like MS-275, M334 and SAHA increase neuronal differentiation and inhibit
oligodendrocytes production in adult subventricular zone precursor cells (Siebzehnrubl et. al.,
2007). Zhou et. al., (2011) have reported that SAHA and sodium butyrate blocks G1 to S cell
cycle progression in the neurosphere formation of adult subventricular cells.

Pro-neural

transcription factors such as Neurog1 and Neurod1 are up regulated. SAHA has also been found
to be neuroprotective in dopaminergic neurons from midbrain primary culture by induction of
neurotrophic factors from astroglia through induction of histone acetylation (Chen et. al., 2012).
Jung et. al., (2008) have reported VPA to induce differentiation and reduce proliferation in rat
cerebral cortex neural progenitor cells via the activation of ERK-P21 Cip/WAFI pathway. HDACi
have also shown roles in directing neuronal, cardiomyocytic and hepatic lineage differentiations
(Kretsovoli et. al., 2012).
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SAHA treatment increased survival of dopaminergic neurons in mesencephalic neuronal
culture, which was evident by increase in percentage of dopamine uptake (Chen et .al, 2012). The
neuroprotective quality of SAHA was attributed to astroglia. SAHA was also found to induce the
release of neuronal survival factors from astroglia by increasing the release of neurotrophic factors
GDNF and BDNF. SAHA induced hyperacetylation of histones and also induced expression of
GDNF and BDNF in mesencephalic neuronal culture (Chen et .al, 2012). A study on effect of
various HDAC inhibitors on survival of rat retinal ganglion cells (RGC) led to the finding that
sodium butyrate and VPA delayed the spontaneous cell death in RGC. However, potent HDACi
TSA did not had the same effect in these cells (Biermann et .al, 2011).
1.7. HDACi in neuronal differentiation
HDACi induce histone acetylation in diseased neurons and may restore transcriptional
balance and hence delay or stop cell degeneration (Sterner and Berger, 2000). The neurotrophic
activities of HDACi may be epigenetically controlled by acetylation of histone as well as nonhistone proteins such as transcription factors (Sterner and Berger, 2000). The regulation of
transcription by epigenetic modifications has been proven to be significant for neurite outgrowth
and neuroprotection in the peripheral nervous system during neuronal development. An increase
in acetylation of histones and transcription factors in neurons has been shown to promote
differentiation of neurons and neurite outgrowth (Gaub et. al., 2010). TSA has been shown to
produce differentiation of retinal ganglion Cells (RGC-5 cells). The differentiation of RGC-5 cells
induced by TSA was transcription dependent, as the neurite outgrowth was blocked in presence of
a RNA polymerase inhibitor alpha amanitin (Schwechter et. al., 2007). The differentiation of
RGC-5 cells with HDAC inhibitors might be due to removal of neuron gene-specific transcription
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repressor neuron restrictive silencing factor (NRSF) from NRSE. This process is critical though
not necessarily adequate component of in vivo neuronal differentiation (Schwechter et. al., 2007).
Tomioka et. al., (2014) have shown that TSA induced neurite outgrowth in PC12 cells by
expression of nur77, which was up-regulated due to acetylation of Lys 14 on histone H3. Wang
et. al., (2014) have shown that TSA increased the expression of neurotrophic factors in the Schwan
cells (SC) and inhibited the expression of genes associated with myelin production. TSA was
shown to play an important role in the growth and biological functions such as survival,
proliferation, migration and myelination of SCs (Wang et. al., 2014).
In cultured cortical granule neuron (CGN), hyperacetylation stimulates neuronal outgrowth
and growth cone remodeling through inhibition of HDAC I and HDAC II by a transcriptiondependent mechanism. It was found that TSA induced significant increase in expression of HATs
such as CBP, p300 and P/CAF in cultured CGN. Acetylation dependent –p53 signaling are also
important events in allowing physiological pro-outgrowth signal in primary neuron (Gaub et.al,
2010).
Transcriptional control, chromatin remodeling and epigenetic modifications regulates the
self-renewal and differentiation of neuronal stem cells (NSC) (Temple, 2001). During the
development of the central nervous system in vertebrates, the fate of NSC is firmly controlled
under temporal and regional manners and is also regulated by epigenetic controls (Temple, 2001).
Reports have indicated that the HDACs play important role in controlling proliferation and
differentiation of neural stem cells (Sun et. al., 2011). HDAC1, 3, 5, and 7 are expressed in neural
stem cells. However, the expression of these HDACs is significantly reduced upon differentiation
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(Sun et. al., 2007). HDAC2 is expressed in proliferating neural stem cells and its expression is up
regulated as neurons differentiate (Macdonald and Roskamas, 2008).
A study on the effect of TSA on multipotent neural stem cells, that have the ability for self
renewal and differentiation into neurons astrocytes and oligodendrocytes, demonstrated that TSA
dose dependently, promoted neurite outgrowth in multipotent neural stem cells by significantly
increasing branching points and dendritic area. However, TSA inhibited the differentiation of
NSC into astrocytes. TSA also mediated cholinergic differentiation of NSC as evident by a 10%
increase in cholinergic neurons after TSA treatment (Balasubramaniam et. al., 2006). HDAC
inhibitors have also been shown to increase neuronal differentiation of embryonic mouse neural
stem cells (Siebzehnrubl et. al., 2007). VPA treatment, at the progenitor stage of hippocampal
treatment, led to strong inhibition of cell proliferation and induction of neuronal differentiation
due to an increase in expression of proneural transcription factor. The treatment with HDACi,
increased expression of Ngn, Math1 and P15 and shifted the cells towards neuronal fate. Also, the
increased expression of proneural transcription factor was linked to acetylation of histone H4 (Yu
et. al., 2009).
Similar to neural stem cells, the pluripotent stem cells have also shown potential for the
treatment of neurodegenerative disease owing to their capability to self-renew and differentiate
into all cell types (Thomson et. al., 1998). Pluripotent stem cells (iPSCs) are very similar to
embryonic stem cells and are produced from epigenetic reprogramming of somatic cells through
the exogenous expression of four pluripotency-related transcription factors (Hochedlinger and
Plath, 2009). HDAC inhibitors have been shown to improve the efficiency of reprogramming of
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somatic cells into pluripotent cells (iPSC). HDACi like, SAHA, TSA and VPA have shown
important role in reprogramming of mouse embryonic fibroblast to iPSCs. (Huangfu et. al., 2008).
HDAC inhibitors have also been shown to play important role in survival, proliferation and
differentiation of rat neural precursor cells (NPC). TSA treatment of NPC derived from Sprague
Dawley rats E14.5 brain have shown decreased proliferation and increased differentiation of
neurons along with decreased differentiation of astrocytes. Increased neuronal differentiation and
proliferation of NPC was attributed to reduction in transcription of class II HDAC, while the
transcription of class I HDAC was not changed (Liu et. al., 2012). Hisahara et.al., (2008) have
reported important role of SIRT1, a NAD+ dependent class III HDAC in the differentiation of
NPC. The SIRT1 was found predominantly in cytoplasm. However when cultured NPCs were
transferred to differentiation conditions, SIRT1 was expressed in the nucleus. This implicated
modulation of neuronal differentiation by SIRT1 nuclear translocation. SIRT1 plays an important
role in neuronal differentiation as evident by decrease in neuronal differentiation by inhibition of
SIRT 1 by sirtinol, a SIRT1 inhibitor as well as use of siRNA against SIRT1. Over expression of
SIRT1 promoted neuronal differentiation (Hisahara et. al., 2008).
VPA induces neuronal differentiation in adult hippocampal neural progenitor cells (Hsieh
et. al, 2004). VPA treatment increases the level of acetylated histones. The level of acetylated
histones was higher in the neuronal cells as compared to astrocytes and oligodendrocytes. The
acetylation of histones plays an important role in the differentiation of adult hippocampal
progenitor cells; however deacetylation of histones or deacetylase activity plays an important role
in differentiation of oligodendrocytes and astrocytes. The VPA mediated neuronal differentiation
of neural progenitor cells was linked to up-regulation of a neuron specific gene NeuroD, a bHLH
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transcription factor (Hsieh et. al., 2004). In another study, VPA produced differentiation of
cortical neurons by activation of ERK Pathway. Valproate induced phosphorylation of P44/42
ERK were MEK and REF dependent, which was similar to action of neurotrophins (Hao et. al.,
2004). VPA treatment in rat cerebral cortex induced differentiation and reduced proliferation of
neural progenitor cells via activation of ERK-P21 Cip/WAFI pathway mediated by β-catenin
pathway (Jung et. al,. 2008).
Husstege et. al., (2002) developed two models to investigate the role of histone
deacetylation in oligodendrocyte differentiation. Histone deacetylation has also been shown to be
important for oligodendrocyte differentiation. Deacetylation and subsequent methylation of
histones promoted the differentiation of neural stem cells into neurons and glial cells. The HDAC
activity was necessary for oligodendrocyte differentiation from rat cortical progenitor cells
(Husstege et. al., 2002).
Investigation on the effect of VPA on neuronal differentiation with human bone marrowmesenchymal stromal cells (hBM-MSCs) showed that VPA treated MSCs differentiated on
neuronal media and have shown increase in number/length of neurites as compared to
differentiated MSCs. The VPA treated MSCs exhibited cell morphology similar to neurons. There
was a significant increase in expression of neuronal marker such as Nestin, Musashi, CD133, and
GFAP (Jeonga et. al., 2013).
Sodium butyrate promoted neuronal differentiation of medulloblastoma (MB) cells, the
malignant brain tumors of childhood. Sodium butyrate increased the expression of Gria2 a
neuronal differentiation marker in human medulloblastoma cell lines, D283 and DAOY. HDAC
inhibitors have shown to reduce the MB stem cells survival and proliferation (Nor et. al., 2013).
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VPA specifically enhanced neuronal differentiation in human FGF1 gene 1B promoter (540 to +31) driven green fluorescence F1BGFP (+) embryonic stem cells and Neural
stem/progenitor cells (NSPCs) rather than GFP(-) cells (Kao et. al., 2013). NSPCs were the major
cell population responsive for VPA-induced neuronal differentiation than GFP(-) cells. VPA
activates human FGF1 gene promoter through inhibition of HDAC and GSK-3 activities.
Her et. al., (2010) have shown that HDAC inhibitors namely, TSA, sodium butyrate and
VPA, promote differentiation of rat C6 glioma cells through production of neuroactive 5α-reduce
neurosteroid, which stimulated expression of serotonin stimulated brain derived neurotrophic
factor transcription. These HDACi also stimulated production of glial fibrillary acid (GFAP).
Niemann–Pick type C disease (NPC) is a neurodegenerative associated with lipid storage
disorder (Liscum and Klansek, 1998). In NPC1-/-, mice self-renewal and differentiation of neural
stem cells (NSC) are impaired. Treatment of NPC1-/- mice with VPA enhanced neuronal
differentiation and restored impaired astrocytes in NSCs from NPC1−/− mice. There was an upregulation of essential neurotrophic genes (TrkB, BDNF, MnSoD, and NeuroD), through
repression of the REST/NRSF and HDAC complex by the VPA treatment. Up-regulation of
neurotrophic genes enhanced neural differentiation and cholesterol homeostasis in neural stem
cells from NPC1−/− mice (Kim et, al., 2007).
HDAC1 has also been shown to have an important role in regulating the switch between
proliferation and differentiation in retina of zebra fish. The ratio of the number of differentiating
cells to that of proliferating cells was increased in proportion to HDAC activity due to treatment
of zebrafish with TSA, which suggests that HDAC might regulate the crucial step of retinal
neurogenesis in zebrafish (Yamaguchi et. al., 2003).
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1.8. Importance of neuronal differentiation/ neuritogenesis/ neuroregeneration
Neuroregeneration is a new notion that includes neuroplasticity, neurogenesis and
neurorestoration (Enciu et. al., 2011). Earlier it was believed that nerve regeneration in the
mammalian central nervous system (CNS) was irreversible, but recent reports have suggested that
damaged neurons do regenerate in an active process under the presence of stimulatory substances
such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) (Brinton et.al.,
1998; Filbin, 2000; Fournier and Strittmatter, 2011; McKerracher; 2001 and Pesavento, et. al.,
2002). Neurite outgrowth, an important cellular process for neurogenesis, is a complex process
that involves three stages (1) sprouting; the initiation of neurite formation, (2) elongation of axon
and (3) branching of dendrites followed by formation of synapses (Kiryushko et. al., 2004).
Neuritogenesis is a primary cellular differentiation process for formation of new neurons.
Understanding the cellular and molecular mechanisms of this process is important, because
neuritogenesis is required for proper wiring of the brain and nerve regeneration, and has been
associated with various neurodegenerative diseases (Jones et. al., 2001). Recent reports have
emphasized the significance of neurite outgrowth in the process of neuroregeneration and repair
of damaged neurons (Maruoka et. al., 2011). The physiological substances, which trigger the
process of neuritogenesis, are commonly referred as neurotrophic factors. Neurotrophic factors
are proteinacious growth factors that promote neuritic outgrowth, repair damaged neurons and may
play a significant role in restoration and readjustment of normal neuronal functions of the damaged
neurons (Li et. al., 2002). These factors are produced and released by the target neuronal tissues
and initiate the growth and differentiation of developing neurons. The nerve growth factor (NGF),
brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophic factor-4/5
(NT-4/5) are commonly referred as neurotrophins.
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Use of natural neurotrophins seems to be an obvious choice in the process of neuronal
regeneration. However, despite their undeniable positive effects, therapeutic applications of
natural neurotrophins like NGF and BDNF, for treatment of neurodegenerative diseases, are
limited due to their negligible entry through the blood brain barrier and also susceptibility to
degradation by peripheral peptidases (Maruoka et. al., 2011). Recently, there has been significant
surge in identification of small molecular weight neurotrophic compounds, which can promote
growth, differentiation, survival of developing and damaged neurons.
There has been a great deal of research done on using neurotrophins as a possible therapy
for people suffering from disorders involving neuronal degeneration and physical trauma resulting
in the severing of nerve connections. They can help direct and facilitate the survival of neurons
after physical injury (i.e., motorcycle accidents and sports-related injuries) or in neurodegenerative
diseases such as Alzhiemer's, Huntington's, and Parkinson's disease. By applying these growth
factors, primarily in the central nervous system area where neurons have more difficulty in
repairing themselves (in comparison to the better repair capabilities of the Peripheral Nervous
System), researchers today hope to make neurotrophins a more widely accepted clinical possibility
in the field of neuroregeneration.
Recent reports indicates neuroprotective and neurotrophic properties of small molecular
weight inhibitors of histone deacetylases (HDACs) and their potential use in treatment of
neurological disorders (Camelo et. al., 2005; Wiech et. al., 2009 and Xu et. al., 2011). HDAC
inhibitors by chromatin modification and epigenetic regulation may contribute to unique neuronal
adaptations such as transcription-dependent neuroplasticity and learning (Kandel, 2001 and Wu
et. al., 2007) or axon and dendrite regeneration.
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1.9. Concluding Remarks: identification of small molecule neurotropic factors as potential
therapeutic agents for treatment of neurodegenerative diseases
The review of literature presented above describes the current status of the knowledge
about role of various HDAC inhibitors in neuronal differentiation and neuroprotection in different
cell lines and in vivo models.

Therapeutic application of several HDAC inhibitors for

neurodegenerative diseases has also been discussed. As evident by the literature survey, HDAC
inhibitors have significant therapeutic potential for many of the neurodegenerative diseases such
as PD, AD, SMN, ALS, TBI, MS and HD. HDAC inhibitors brings about neuronal differentiation
in neural stem cells (NSC), neural progenitor cells (NPCs), rat retinal ganglion cells (RGCs),
dopaminergic neurons, SHSY5Y neuroblastoma cells, cortical granule neurons (CGN) and cell
line such as PC12 cells. HDAC inhibitors also possess neuroprotective and neurotrophic potential.
However, potential limitations regarding safety of these HDAC inhibitors cannot be ignored.
Reports indicate that HDAC inhibitors in some instances could play a role in pathogenesis of the
neurodegenerative disease, while in others could act as potential therapeutics for the
neurodegenerative disease. These opposing effects of HDAC inhibitors could be attributed to
varying epigenetic status of the targets, cell type and tissue specificity. On occasion, the HDAC
inhibitors have been shown highly neurotoxic rather than being neuroprotective. The major
problem associated with HDAC inhibitors is their lack of specificity and in particular their lack of
isoform selectivity. Another issue is incomple knowledge about non-target actions. There is a
great surge for learning about mechanism of action and the various ways that HDAC inhibitors
affect gene expression. Future research is expected to elucidate the mechanism of HDACi action
in order to design novel reagents with increased effectiveness and specificity. Research on
specific/selective HDAC inhibitors would be beneficial from therapeutic point of view and would
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likely overcome the problems currently associated with HDAC inhibitors. Hopefully the rapid
interest in the study of HDAC inhibitors will shed some light on the mechanism of action of these
inhibitors and give us direction to combat neurodegenerative diseases.
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1.10. Objectives of the study
Neurite outgrowth is an intricate process that involves three stages (1) sprouting, the
initiation of neurite formation (2) elongation of axon and (3) branching of dendrites followed by
formation of synapses (Kiryushko et. al., 2004).

Neuritogenesis is a fundamental cellular

differentiation process for formation of new neurons. Understanding this process is important,
because it is required for proper wiring of the brain and nerve regeneration, and has been associated
with various neurodegenerative diseases (Jones et. al., 2001). Reports indicate the significance of
neurite outgrowth in the process of neuroregeneration and repair of damaged neurons.
Neurotrophic substances that promote neuritic outgrowth can repair damaged neurons and may
play a significant role in restoration and readjustment of normal neuronal functions of the damaged
neurons (Li et. al, 2002). The use of natural neurotrophic seems to be the obvious choice in the
process of neuronal regeneration. However, despite their undeniable positive effects, therapeutic
applications of natural neurotrophins like NGF and BDNF are limited due to their negligible entry
through the blood brain barrier and also destabilization by peripheral peptidases (Maruoka et. al.,
2011). Bioactive small molecules with neurotrophic and neuritogenic actions may have promising
use as therapeutic agents for treatment of neurodegenerative diseases and neuronal injuries by
virtue of their abilities to stimulate neuritic outgrowth. Studies to identify low molecular weight
compounds that can mimic the function of neurotrophic factors and substitute for their clinical use
are in progress now. The HDAC inhibitors may provide potential new neutrophic drug leads.
Being, low molecular weight compounds, many of the HDACi have the ability to cross blood brain
barrier.

HDACi play significant role in neuronal differentiation, neuroprotection, neurite

outgrowth and in treatment of several neurodegenerative diseases as detailed in the preceeding
review of literature. In most cases molecular mechanisms of HDACi that were associated with
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neuronal protection and differentiation were attributed to the induction of differentiation by
regulation of the transcription factors and transcription. However, further studies are needed to
explain the mechanism of HDACi actions in order to design novel reagents with increased
effectiveness and specificity (Kretsovali et. al., 2012). Present studies aim to identify selective,
pan and isoform specifics HDAC inhibitors with neurotrophic potentials i.e. ability of the HDACi
to induce neurite outgrowth in vitro in appropriate cell lines and understanding the molecular and
cellular mechanisms of their action.
We have used Neuroscreen-1 (NS-1) cell line, a subclone of PC12 cells, as a model for
studying the effect of HDACi on neurite outgrowth. Pheochromocytoma (PC12) cell-line, clonal
cells originated from a transplantable rat pheochromocytoma, is a widely used in-vitro model to
study neuronal differentiation. PC12 cells have important feature, when treated with NGF, they
undergo a dramatic change in phenotype and acquire a number of characteristic properties of
sympathetic neurons. NGF-treated PC12 cells stop proliferation and start differentiation by
extending neuritis and become electrically excitable (Westerink and Ewing, 2008). However, in
spite of their wide use, PC12 cells have some limitations. Although the PC12 cells can acquire
properties similar to sympathetic neuron, they lack development of definitive axons or dendrites
and do not form true synapses with each other. Additionally, the PC12 cells also have the potential
for genetic drift with respect to repeated cell passage with a concomitant change in phenotype
(Banker and Goslin, 1998). NS-1 cell line shows improved adherence, shorter doubling time and
higher responsiveness to NGF than parent PC12 cell culture (Dijkmanas et. al., 2008).
Considering the critical issues mentioned above, we selected NS-1 cell line as a cellular models
for the investigations related to in vitro neuritogenesis/neurite outgrowth. Present study aims to
identify selective, pan and isoform specifics HDAC inhibitors with neurotrophic potentials i.e their
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ability to induce neurite outgrowth in Neuroscreen-1 cell and understanding the molecular and
cellular mechanisms of their action. The specific aims of this study are outlines below :Aim 1: Screen pan and selective HDAC inhibitors for neurotrophic potential and induction of
neuritogenesis in NS-1 cells
Aim 2: To investigate cellular and molecular mechanism of neurotrophic HDAC inhibitors
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CHAPTER 2
EXPERIMENTAL METHODS

2.1. Cell culture
PC12 is a widely used cell line, which was originally derived from a pheochromocytoma
of the rat adrenal medulla (Giordano and Costa, 2011). PC12 cells display an important feature,
in that when treated with NGF, they undergo a dramatic change in phenotype and acquire number
of characteristic properties of sympathetic neurons. Additionally, the ease of maintaining and
growing these cells in vitro and their characteristic pharmacological responses have allowed the
application of PC12 cells as a standard model system for neurons (Green and Tischler, 1982). The
treatment of PC12 cells with NGF stops proliferation and starts their differentiation by extending
neurites, which are electrically excitable (Green and Tischler, 1982).
Neuroscreen-1 (NS-1) cells were procured from Cellomics (Pittsburg, PA, USA). NS-1
cells, a sub-clone derived from the PC12 cell culture, display several substantial advantages over
PC12 cells, including faster growth, no aggregation and better responsiveness to NGF (Dijkmans
et. al., 2008). NS-1 cells were cultured in RPMI 1640 medium containing 10% horse serum, 5%
fetal bovine serum, 2mM L-glutamine, 100 units/mL penicillin and 100µg/ml streptomycin and
incubated at 37ºC, in a 5% CO2 and 95% humidified incubator. The NS-1 cells were sub-cultured
after 2-3 days or twice a week for maintaining culture.
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2.2. In vitro cytotoxicity & neuritogenesis assay
2.2.1. Cell Differentiation
NS-1 cells were seeded onto a collagen IV coated clear 96 well plate (BD Biosciences)
with 2000 cells/well. The cells in RPMI-1640 growth medium were allowed to adhere onto the
plate surface for 24 hours. The cultures were treated with specified concentrations of HDAC
inhibitors, NGF and other signaling inhibitors as specified for 48 hours.
2.2.2. Cell Viability/Cytotoxicity Assay
Cell viability/cytotoxicity was determined using alamarBlue colorimetric quantitative
method. This method uses a resazurin reduction assay. In physiologically active cells resazurin is
reduced to resorfurin giving a bright red fluorescence. After 48 hours of treatment with test
compounds and/or NGF, 10µl of the alamarBlue reagent was added directly to the media in each
well. Plates were further incubated overnight. The fluorescence was measured at 544nm excitation
and 590nm emission and the data were analyzed to determine viability/cytotoxicity.
2.2.3. Staining and Images:
After reading the plates for cell viability, plates were washed with phosphate buffered
saline (PBS), fixed with methanol and stained with Giemsa for 1 hour. The plate was then washed
with distilled water, dried under air and subjected to digital imaging under a bright light
microscope for measurement of neuritogenesis. At least three images were captured from each
well, and analyzed by NIS element software for quantification of neuritogenesis. Representative
photomicrographs were captured with a Nikon digital camera attached to the microscope. From
each well, multiple fields per well were selected manually and images were captured. The images
were captured using 10X objective and the images were stored as JPEG files.
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2.2.4. Analysis of NS-1 cells’ digital images for neurite outgrowth
For each treatment, at least 50 cells were analyzed from the images captured from each
well in triplicate. Neurite length was calculated by tracing the neurites in each cell by computer
mouse using Nikon NIS element software (Figure 2.1). Mean neurite length and number of
neurites were calculated from a known number of cells counted. The data obtained was exported
to an MS Excel file. The values from the MS Excel file were copied and pasted into a macrobased MS Excel template, which was designed to measure neurite outgrowth. The neuritogenesis
was assessed according to the following parameters: (a) mean neurite length (ratio between sum
of length of total neurites measured to the number of neurites measured); (b) neurite length/cell
(ratio between sum of length of total neurites measured to the number of cells counted); (c)
neurites/cell (total number of neurites/ number of cells counted).

[A]

[B]

[C]

Figure 2.1. Measurement of neurite out growth in NS-1 cells by analysis of digital cell images with
NIS element software. [A] Untreated cells [B] Cell treated with NGF and [C] An enlarged digital
image showing neurites and neuritic nodes.
To evaluate the signaling pathways involved in vorinostat induced neuritogenesis, cell
cultures were pretreated with MEK1/2 inhibitors (PD98059 and U0126) (10 µM), PI3K inhibitor
(LY294002) (10 µM), Trk inhibitor (GW441756) (1 µM) or the adenylate cyclase inhibitor
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(SQ22536) (200 µM) as specified in more details in results, followed by treatment with vorinostat
(1 µM) and/or NGF (2.5 ng/ml) (positive control) for an additional 72 hrs. DMSO was used as
the negative control in each assay. Cytotoxicity and neurite outgrowth assays were also performed
as described above.
2.3. Analysis of phosphorylation of ERK1/2 by Western blotting
NS-1 cells (2.5 X 105 cells/mL) were seeded onto collagen coated 25 cm² cell culture flasks
and allowed to adhere for 24 hrs. At least two 25 cm² cell culture flasks were set up for each
treatment. Cells were treated with vorinostat (1 & 2.5 µM) and NGF (2.5 ng/mL) with and without
U0126 for 5, 15, 30, 60 and 120 minutes. Two control flasks were set-up for DMSO for each set
of assay. The culture medium was aspirated from the treated flasks and the cells were washed
with ice cold 1X PBS. Lysis of cells was done with the 1X cell lysis buffer (20mM Tris HCL pH
(7.5), 150mM NaCl, 1mM Na2 EDTA, 1mM EGTA, 1% Triton, 2.5mM sodium pyrophosphate,
1Mm β-glycerophosphate, 1mM Na3V04, 1μg/mL leupeptin). Cells were treated with 100 µl of
1X cell lysis buffer per well for 6-well plate. Immediately after the lysis, the cells were scraped
off the plate and the cell lysates were transferred to 1.5 mL micro-centrifuge tubes. The tubes with
the cell lysates were kept on ice till further treatment. The cell lysates were sonicated by
sonicator/cell disruptor model W-10 from Health System Ultrasonics for 10–15 secs for 3 times to
complete cell lysis and shear DNA (to reduce sample viscosity). The extract was spun in a cold
microcentrifuge at 14,000xg for 10 min. The supernatant was removed for further use. An equal
volume of 2X SDS sample buffer (4%SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004%
bromophenol blue and 0.125 M Tris Hcl) was added to the cell lysates. The samples were heated
to 95–100°C for 5 min and further cooled on ice. The protein contents in each lysate was estimated
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with Bradford assay using Quick startTM Bradford 1x dye and following the standard protocol
provided in the user manual.
The 20 μg of samples were loaded onto 10% (10 cm x 10 cm) SDS-PAGE mini gels (BioRad, USA). The electrophoresis was done at 200 V for 40 minutes. The proteins from SDS-PAGE
gel were electro-transferred to nitrocellulose membrane using Bio-Rad –Transblot Turbo transfer
system. The transfer was done at 1.3A-2.5 V for 7 minute using Bio-RAD protocol. After transfer,
nitrocellulose membranes were washed with 25 mL 1X Tris buffered saline (TBS) for 5 min at
room temperature. The membranes were incubated in 25 mL of blocking buffer (5% nonfat dried
milk in 1x TBST [20 mM Tris–HCl (pH 7.5), 137 mM NaCl and 0.01% (v ⁄ v) Tween 20] for 1 hr
at room temperature. After the incubation, the membranes ware washed three times (for 5 min
each) with 15 mL of TBST. The membranes were further incubated overnight at 4°C with the
primary antibody (at 1:1000 dilution) in 10 mL primary antibody dilution buffer (1X TBST with
5% BSA) with gentle agitation.

The membranes were probed overnight with phospho-

p44/p42MAPK (ERK1/2) antibody (Cell Signaling Technology, USA) for measuring
phosphorylated ERK1/2 and p44 MAPK (ERK1) antibody (Cell Signaling Technology, USA) for
total ERK levels, following the manufacturer’s protocols. The membranes treated with the primary
antibody were washed three times (for 5 min each time) with 15 mL of TBST and incubated further
with the anti–rabbit HRP-conjugated secondary antibody (1:2000 dilution in 10 mL blocking
buffer) with gentle agitation for 1 hr at room temperature. Each membrane was developed with
enhanced chemiluminescence (ECL) kit (GE Healthcare), following the manufacturer’s protocol.
The images were captured, processed and analyzed on a Bio-Rad ChemiDoC MP imaging system.
For analysis of acetylated histones H3 and H4 and acetylated α-tubulin, the cell lysates were
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probed with antibodies against acetyl-histone H3 (Lys 9) and acetyl-Histone H4 (Lys 8) and acetyl
α-tubulin (Lys 40).
2.4. Immunolocalization of acetylated α-tubulin in NS-1 cells
The NS-1 cells were seeded onto ibidi microchamber collagen IV coated 4 well plastic
micro slides (1X10⁵ cells/well in RPMI1640 medium). The cells were allowed to adhere for 24
hrs. The cells were treated with vorinostat (1 and 2.5 µM) or 2.5 ng/mL NGF for 6 hours. The
culture medium was aspirated and the cells were fixed by adding 400 µl of 4% paraformaldehyde
diluted in warm PBS for 15 min at room temperature. After fixative was aspirated the chambers
were rinsed three times with 1X PBS and slides were processed further for immunostaining.
2.5. Immunostaining
The cells were treated with the blocking buffer (1X PBS/5% normal serum/0.3% Triton™
X-100) for 60 minutes, followed by treatment with primary antibody-α-Tubulin (Lys40) (D20G3)
XP® (1:800 dilution) overnight at 4 °C. Slides were rinsed three times with 1XPBS for 5 min each.
The slides were incubated for 1 to 2 hrs at room temperature in the dark, with the secondary
antibody (Anti rabbit IgG (H+L), F(ab')2 Fragment, Alexa Fluor 488 Conjugated) (Cell Signaling
Technology) diluted 1:1000 in antibody dilution buffer (1X PBS/1% BSA/0.3% Triton™ X-100).
The slides were rinsed 3 times with 1XPBS and treated with 300 μl of diluted DyLight™ 554
Phalloidin (an actin staining dye) for 15 mins at room temperature. Dilution used for phalloidin
was 1:200, 0.5 μl in 100 μl assay volume PBS. The slides were rinsed once with 1XPBS and
finally treated with 300 μl DAPI (4’, 6-diamidino-2-phenylindole) (0.1 μg/mL), a nuclear staining
dye. The slides were rinsed 3 times with 1XPBS for 5 min each,150 µl of DABCO (2% DABCO,
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80% glycerol in PBS) mounting media was added into each well, covered with the lid and the
slides were further examined under the confocal microscope Zeiss 510 using filters 420-480, 505550, or 560-615.
2.6. Cell cycle Analysis by Flow Cytometer
The HDAC inhibitors were also evaluated for their effect on NS-1 cells growth cycle in in vitro
culture. For cell cycle studies 1x105 NS-1 cells/mL were seeded into a 25 cm² collagen I coated
cell culture flask in a total volume of 5 mL. The cells were allowed to adhere for 24 hours. The
NS-1 cell cultures were treated with 1μM vorinostat and/or 2.5ng/mL NGF for 24 and 48 hours.
The cells were harvested by scrapping in ice cold 1xPBS. The washed cells from different culture
flasks were collected in tubes, centrifuged at 200xg for 5 minutes at 40C. Cells were resuspended
in 1 mL ice cold 1XPBS. These cell suspensions were added to 9 mL of cold 70% ethanol with
constant gentle shaking. The cell suspensions in 70% ethanol were kept at 40C for 2 hrs. After
fixation in ethanol, the cell suspensions were centrifuged at 200g for 10 min at 4°C. The cell
pellets were washed with ice cold 1XPBS by centrifuging at 200g for 10 min at 4 °C. The pellets
were resuspended in RNase A (3 mL; 100 µg/mL in 1XPBS) and the tubes were incubated at 37°C
for 30 min. The RNase solution was removed by centrifugation of the cell suspensions at 200 g
for 10 min at 4°C. The supernatants were discarded and the cells were stained by adding 1mL of
50µg/mL of propidium iodide solution in PBS for 30 min at 4°C. Further the analysis of cell cycle
was done using BD Facscalibur through Cell proquest. Total gated and ungated events recorded
were 5000. The cell cycle data acquired were analysed with flowJo software.
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2.7. HDAC Assay:
HDAC assay was done using Fluoro-de-lys HDAC Fluorometric acivity assay kit (BMLAK500-0001) (Enzo Life Science, USA).
Treatment
The NS-1 (2.5x105 cells per 25cm2 culture flask in total volume of 5mL) were seeded for
24 hours. The cells were treated with 25 nM trichostatin A for 8, 24, 72 and 96 hours, the cells
were washed with 1XPBS and harvested. The cell pellets were resuspended in 1X cell lysis buffer
(Cell Signaling Technology, USA). Protein contents in cell lysates were determined by Bradford
assay (Bio-Rad, USA). The cell lysates were diluted with HDAC assay buffer (50 mM Tris/Cl,
pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) to get 20 µg protein/25 µL of the lysate.
Reagent /Dilution preparation
Fluoro de-lys substrate was diluted 1:200 times in HDAC assay buffer (50 mM Tris/Cl, pH
8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2). Fluor de LysDeveloper (20x Stock Solution),
diluted to 1X time in HDAC Assay Buffer before use and Trichostatin A (0.2 mM in DMSO
(dimethylsulfoxide). e.g. 10μl in 1 mL; final Trichostatin A concentration in the 1x Developer =
2μM; final concentration on after addition to HDAC/Substrate reaction = 1μM. The cell lysates
were diluted with HDAC assay buffer -to get 20 µg protein/25 µL of the lysate. The Hela nuclear
cell extract, supplied with the HDAC assay kit, was used as positive control.
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Assay protocol
Assay buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2), or test
inhibitor/sample was added to appropriate wells of the microtiter plate (Table). Diluted HeLa
extract or other TSA treated cell lysate was added to all wells except those that are to be “No
Enzyme Controls” (Table 2.1). Diluted Fluor de Lys Substrate and the samples in the microtiter
plate were allowed to equilibrate to assay temperature (e.g. 25 or 37°C) for 10 minutes. HDAC
reactions were initiated by adding diluted substrate (25μl) to each well and mixing thoroughly.
HDAC reactions were allowed to proceed for 10 minutes and then stopped by adding 50μl Fluor
de Lys Developer. Plates were incubated at room temperature (25°C) for 10-15 min. Signal is
stable for at least 30 min beyond this time. Samples were read in a microtiter-plate reading
fluorimeter capable of excitation at a wavelength in the range 350-380nm and detection of emitted
light in the range 440-460nm.
Table 2.1

Assay

Substrate

buffer

Mix

well

pipetting

by Developer
and

Incubation

incubate for 10
25µl

50µl

Sample

25µl

25µl

50µl

Zero time

25µl

25µl

50µl

min

(No enzyme)

For zero time add substrate just before adding developer
Table 2.1. Template for HDAC assay
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room

temperature for 15 min

25µl

Blank

at

Take reading

2.8. Statistical analysis
All quantitative data is presented as mean and standard deviations as computed with MS
Excel and GraphPad Prism 6 software. The individual data sets were statistically analyzed by
Students t test and p values were computed to determine statistically significant differences
between two groups. One-way analysis of variance (ANOVA) followed by Bonferroni test were
used to compare multiple groups.

The p values were computed to determine statistically

significant differences among the groups.
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CHAPTER 3
EXPERIMENTAL RESULTS
3.1. Aim 1: Screen pan and selective HDAC inhibitors for neurotrophic potential and
induction of neuritogenesis in NS-1 cells
A large number of natural and synthetic compounds are currently known to inhibit HDACs
(Dokmanovic et. al., 2007). The HDACi do not inhibit all HDAC isoforms to the same extent.
The HDACi have been grouped into pan and selective HDACi based on their isoform selectivity
and other inhibition characteristics (Balasubramanian et. al., 2009). Hydroxamic acids (e.g. TSA,
SAHA, LAQ824, and CBHA) and pyroxamic acids (PXD101 and CRA-026440) are pan-HDAC
inhibitors, which target class I, II and IV HDACs with variable sensitivities. Selective HDAC
inhibitors are relatively specific against individual HDAC isoforms, which may exhibit reduced
side effects compared to the pan-HDAC inhibitors, while retaining efficacy in specific subsets of
indications, where each HDAC isoform plays a critical role. Benzamides (MS275 and CI-994),
cyclic tetrapeptides (Trapoxin A and depsipeptides) selectively inhibit class I HDACs (Xu et. al.,
2007). Depsipeptide is currently in a phase II clinical trials for Cutaneous T-cell Lymphoma
(CTCL) and peripheral T-cell Lymphomas (PTCL) (Rasheed et.al, 2007). Selective HDACi also
provide important tools to investigate the role(s) of specific HDAC isoforms in target functions.
In order to identify the HDACi with potential neurotrophic action, we have evaluated both pan- as
well as selective HDACi for their neuritogenic action in vitro in NS-1 cells culture. The HDACi
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were tested alone and also in combination with NGF, the natural neurotrophin. Six HDACi namely,
SAHA, TSA and Belinostat (as the highly potent pan- HDACi), tubastatin A (a highly selective
HDAC6 inhibitor), PCI-34051 (a selective HDAC8 Inhibitor) and Tenovin-1 (a selective inhibitor
of sirtuins SirT1 and SirT2) were selected for initial investigations for neurotrophic action and
induction of neurite outgrowth in NS-1 cells. More details about the individual inhibitors are
summarized as below.
3.1.1. PCI-34051
PCI-34051 is a selective HDAC8 inhibitor derived from the low molecular weight
hydroxamic acid scaffold. PCI-34051 inhibits HDAC8 with a Ki of 10 nM and has greater than
200 fold selectivity over the HDACs 1, 2, 3, 6 and 10. PCI-34051 has been shown to induce
apoptiosis in the T-cell lymphoma cells like Jurkat and HuT78 cells at very low micromolar doses
(Balasubramanian et. al., 2008). However, the apoptoic effect of PCI-34051 is seen only in the
cell lines derived from T-cell lymphoma, but not in solid tumors, plasma cells, monocytes or the
cell lines derived from B-cells, even at doses as high as 20 μM. The cell death induced by PCI34051 is caspase dependent and also requires phospholipase C gamma 1 (PLC λ 1) enzymatic
activity. Induction of PLCλ1 increases calcium mobilization, which in turn results in uptake of
calcium into mitochondria, release of cytochrome c into the cytosol and activation of caspase
(Balasubramanian et. al., 2008).
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Figure 3. 1. Chemical structure of PCI-34051.
3.1.2. Tubastatin A
Tubastatin A is a highly potent selective HDAC6 inhibitor with an IC50 of 15 nM.
Tubastatin A is substantially more selective than the previously known HDAC 6 inhibitor, tubacin.
Tubastatin A has been known to induce α -tubulin hyperacetylation in primary cortical neurons.
Tubastatin A has also shown dose-dependent protection of primary cortical neuron cultures against
glutathione depletion-induced oxidative stress (Butler et. al., 2010). The α-tubulin is the most
abundant substrate for tubastatin (Hubbert et. al., 2002). Other HDAC6 substrates include HSP90,
Cortactin and β-Catenin (Kovacks et. al., 2005; Zhang et. al., 2007; Li et. al., 2008). The HDAC6
also binds with ubiquitin and regulates cell protective response to cytotoxic accumulation of misfolded and aggregated proteins (Ouyang et. al., 2012). In several CNS diseases, HDAC6 has
emerged as a useful target for pharmacological intervention. Selective inhibition of HDAC6 is
associated with neuronal survival and regrowth after injury, thereby having a huge potential for
treatment of neurodegenerative disease (Kazantsev and Thompson, 2008; Rivieccio et. al., 2009;
Butler et. al., 2010).
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Figure 3. 2. Chemical structure of tubastatin A.
3.1.3. Tenovin-1
Tenovin-1 inhibits SIRT1 and SIRT2, the members of the NAD+-dependent class III
HDACs. Tenovin-1 decreases the protein deacetylase activities of purified human SirT1 and SirT2
(Lain et. al., 2008). It has been shown to affect acetylation of SirT1 and SirT2 substrates in cells.
SirT1 substrate includes histones H1, H3 and H4. SirT1 can induce silencing of chromatin by
inducing deacetylation of histones H1, H3 and H4 (Vaquero et. al., 2004). SirT2 is cytoplasmic
protein and it deacetylases large number of cytoplasmic substrates including α-tubulin (North et.
al., 2003). Tenovin-1 is the only sirtuin inhibitor, for which overexpression of SirT1 or SirT2 has
been shown to impair their effects (Lain et. al., 2008). Tenovin-1 has been shown to activate and
elevate acetylated p53 levels, induce apoptosis in vitro, and acetylate histone H4. Tenovin-1 also
activates p21 and p53. Tenovin-1 increases the protein level of p53 within 2 hours of treatment of
MCF-7 cell lines. However the mRNA level for p53 was not affected by tenovin-1 (Lain et. al,
2008)
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Figure 3. 3. Chemical structure of tenovin-1.
3.1.4. Belinostat (PXD 101)
Belinostat is a new hydroxamate derivative and is believed to inhibit class 1 and class 2
HDACs. Belinostat is in late stage clinical development for Peripheral T-cell Lymphoma (PTCL).
Belinostat increases acetylation of both histones and non-histone proteins, resulting in cell cycle
arrest, apoptosis and a decrease in cell proliferation in tumor cell lines. In vitro experiments
showed that belinostat had potent anti-tumor effect at low micromolar potency in several tumor
cell lines. Belinostat inhibited tumor growth in animal models at non-toxic concentrations
(Tumber et. al., 2007; Plumb et.al, 2003; Qian et. al., 2006). Phase I clinical studies have also
suggested that belinostat has anti-tumor effect (Hansen et. al., 2005; Marks et. al., 2001).
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Figure 3. 4. Chemical structure of belinostat.
3.1.5. Trichostatin A (TSA)
TSA is an antifungal antibiotic, which inhibits the class I and II HDACs. TSA is the most
potent of all the HDAC inhibitors. It belongs to the group of hydroxamic acid HDACi. TSA
inhibits the eukaryotic cell cycle during the beginning of the growth stage (Drummond et. al.,
2005), induces cell differentiation, cell cycle arrest, and reversal of transformed cells morphology
(Yoshida et.al., 1995).

Figure 3. 5. Chemical structure of Trichostatin A.
3.1.6. Suberoylanilide hydroxamic Acid (SAHA)
SAHA is the first HDACi approved by the U.S. Food and Drug Administration (FDA) for
the treatment of Cutaneous T Cell Lymphoma (CTCL). SAHA is a small molecular weight (<300)
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linear hydroxamic acid compound that inhibits HDACs of Class I & II with IC50 in the range of
10-100 nM. SAHA is also referred as vorinostat and marked under the trade name Zolinza. By
inhibition of HDAC activity, SAHA induces the accumulation of acetylated histones as well as
non-histone proteins, blocks the proliferation of cultured cells and inhibits tumor growth in a
variety of animal models (Marks et. al., 2001; Marks and Dokmanovic, 2005). Administration of
SAHA orally is able to cross the blood brain barrier, increases histone acetylation and improves
motor impairment in the R6/2 mouse model of Huntington’s disease (Mitsiades et. al., 2004).

Figure 3. 6. Chemical structure of vorinostat.

49

3.2. Results
The NS-1 cell cultures were treated with different concentrations of NGF and neurite
outgrowth was determined as described in experimental section. A dose-dependent effect of NGF
was confirmed in vitro on NS-1 cells. The NS-1 cells were observed to be significantly more
responsive than the regular PC12 cells to neurotrophic effects of NGF. Treatment with as low as
1.25 ng/mL concentration of NGF was able to trigger differentiation and neuritic outgrowth
measured in terms of mean neurite length in NS- 1 cells as shown in Figure 3.7. At doses 25 and
50 ng/mL, the saturation of neurite outgrowth was observed.
The concentrations of 1.25 and 2.5 ng/mL NGF were observed to be significant and suboptimal for the neurite growth. These concentrations of NGF were employed in subsequent
experiments for evaluation of neurotropic potential of HDAC inhibitors and also for interrogation
of relevant signal transduction pathways.
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Figure 3.7. Dose response curve of NGF on mean neurite length. NS-1 cells were treated with
varying concentration of NGF ranging from 0-50 ng/mL. After 72 hours of incubation, cells were
stained and mean neurite length was calculated by analysis of the digital images of the cells. Dose
response curve was plotted with concentration of NGF (ng/mL) against mean neurite length. Error
bars shown here are SD of three independent readings.
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3.2.1. Evaluation of neurotrophic effects of PCI-34051
Three concentrations (1, 2.5 and 5 μM) of PCI-34051 were tested on NS-1 cells to evaluate
the effect of this HDACi on the neuritogenesis. PCI-34051 was tested alone and also in
combination of NGF (2.5 ng/mL). The NGF alone (2.5 ng/mL) was tested as a positive control.
All the doses tested were not cytotoxic to the NS-1cells. The PCI-34051 mediated neuritogenesis
was compared with positive control NGF (2.5 ng/mL) and untreated NS-1 cells. Neurtiogenesis
was measured in terms of three end points namely, mean neurite length (Figure 3.8.A), numbers
of neurites/cell (Figure 3.8.B) and neurite length/cells (Figure 3.8.C). Treatment with PCI at 1 and
2.5 μM did not produce significant increase in mean neurite length. However, PCI-34051 at 5μM
produced significant increase in mean neurite length, neurite length/cell as well as a number of
neuritis/cells. Thus PCI-34051 at 5 µM produced significant and prominent induction in neurite
outgrowth, as determined by significant increase in all the three parameters of neurite outgrowth.
Co-treatment of NS-1 cells with PCI-34051 and NGF produced neuritogenic effect similar to that
shown by NGF alone. PCI-34051, therefore, did not cause significant effect on the NGF-stimulated
neurite outgrowth.
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Figure 3.8. Effect of PCI-34051 on neurite outgrowth in NS-1 cell. Cells treated with 1, 2.5
and 5 μM PCI-34051 with and without NGF 2.5 ng/mL for 72 hours. Neurite outgrowth
significantly increased in PCI-34051 (5 μM) treated cells as indicated by three measured
parameters in terms of three end points namely, [A] mean neurite length [B] numbers of
neurites/cell and [C] neurite length/cell. Data represented are mean ± SD of three independent
experiments. * P< 0.05, ** P< 0.001 compared to control untreated cells.
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3.2.2. Effect of tubastatin A on neurite outgrowth
The NS-1 cell cultures were treated with tubastatin A 1, 5 and 10 μM. Cytotoxicity of the
inhibitor at these doses was also tested. All the doses of tubastatin A tested for induction of
neuritogenesis were non-toxic to the NS-1 cells. Tubastatin A at any dose tested alone did not
induce significant neurite outgrowth in NS-1 cells measured in terms of three end points i.e. mean
neurite length (Figure 3.9. A), neurites/cell (Figure 3.9. B) and neurite length/cell (Figure 3.9. C).
However, only at 5 μM concentration of tubastatin A, there was a significant increase in number
of neurite/cells as compared to the control untreated cells. NS-1 cells treated with NGF and
tubastatin A also had significant neurite outgrowth.
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Figure 3.9. Effect of tubastatin A on neurite outgrowth in NS-1 cells. The NS-1 cell cultures
were treated with tubastatin A 1, 5 and 10 μM with and without NGF (2.5 ng/mL) for 72 hours.
Neurite outgrowth was measured in terms of three end points namely, [A] mean neurite length [B]
numbers of neurites/cell and [C] neurite length/cell. Data represented are mean ± SD of three
independent experiments. P value were calculated using student test,* denotes P< 0.05, ** denotes
P< 0.001 and NS indicates non-significant difference compared to control untreated cells.
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3.2.3. Effect of tenovin-1 on neurite outgrowth.
Tenovin-1, an inhibitor SirT1 and SirT2, was evaluated at three concentrations namely,
2.5, 5.0 and 10 μM for the potential to induce neurite outgrowth in NS-1 cells. Cytototoxicity of
tenovin-1 was also monitored. Tenovin-1 did not show noticeable toxicity on NS-1 cells. Also,
tenovin-1 alone at any of concentrations tested did not significantly increase the neurite outgrowth
in terms of mean neurite length and neurite length/cell. However, tenovin-1 at 5 and 10 μM
concentrations led to a significant increase in number of neurite/cell. Interestingly, tenovin-1
significantly inhibited the NGF-mediated neuritogenesis in terms of mean neurite length (Figure
3.10.A), neurites/cell (Figure 3.10.B) and neurite length/cell (Figure 3.10.C).
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Figure 3.10. Effect of tenovin-1 on neurite outgrowth in NS-1 cell. Cells were untreated and
treated with tenovin-1 2.5μM, 5 μM and 10 μM with and without NGF 2.5 ng/mL for 72 hours.
Tenovin-1 alone at any concentration tested did not significantly increased the neurite outgrowth
in terms of mean neurite length and neurite length/cell. However, tenovin-1 at 5 μM and 10 μM
concentration lead to a significant increase in neurite/cell., tenovin-1 significantly inhibited the
neurite outgrowth induced by NGF as indicated by three measured parameters in terms of three
end points namely, [A] mean neurite length [B] numbers of neurites/cell and [C] neurite
length/cell. Data represented are mean ± SD of three independent experiments. P value were
calculated using student t test, * denotes P< 0.05, ** denotes P< 0.001 and NS indicates non
significance compared to control untreated cells.
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3.2.4. Effect of belinostat on neurite outgrowth
Belinostat, a pan HDACi also referred as PDX 101, has been clinically approved by the
US-FDA for the treatment of peripheral T-cell lymphoma. Belinostat was tested for neurotrophic
action at 0.25 and 0.5 μM concentrations. Both the concentrations of belinostat tested did not
affect the viability and growth of the NS-1 cells. Also, belinostat alone did not induce neurite
outgrowth in NS-1 cells. However, belinostat significantly inhibited the neurite outgrowth in NGF
treated cells. The neurite outgrowth was measured in terms of mean neurite length, (Figure 3.11.A)
neurites per cell (Figure 3.11.B) and neurite length/cell (Figure 3.11.C. The NS-1 cells treated
with belinostat and NGF showed significantly lower neurite length compared to those treated with
NGF alone.
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Figure 3.11. Effect of belinostat on neurite outgrowth in NS-1 cells. Cells were treated with
belinostat (0.25, and 0.5 μM) with and without NGF (2.5 ng/mL) for 72 hours. Neurite outgrowth
was measured in terms of three end points namely, [A] mean neurite length [B] numbers of
neurites/cell and [C] neurite length/cell. Data represented are mean ± SD of three independent
experiments. P value were calculated using student test,* denotes P< 0.05, ** denotes P< 0.001
and NS indicates non-significant difference compared to control untreated cells.
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3.2.5. Effect of Trichostatin A on NS-1 cells differentiation
TSA at the concentrations higher than 25 nM resulted in >30% decrease in viability of NS1 cells. However, TSA caused significant lower cytotoxicity in NS-1 cell cultures co-treated with
NGF. Co-treatment with TSA (50 nM) and NGF (1.25 ng/mL) was found to be non-toxic. TSA
however did not show noticeable neurotropic action as evaluated by overall neurite outgrowth in
NS-1 cell cultures treated with TSA alone and co-treated with TSA and NGF. In order to check
whether TSA is bringing about any change in HDAC activity, the NS-1 cell cultures were treated
with TSA 50 nM and NGF 1.25 ng/mL for 8, 24, 72 and 96 hours. HDAC activity in the cell lysate
was determined using fluor-de-lysHDAC fluorometric activity assay kit from ENZO life sciences.
The results showed that HDAC activity was lowest at 8 hours in TSA treated cells as
compared to the untreated and NGF treated cells. However, at 24 and 72 hours in TSA treated
samples, the HDAC activity was recovered and followed the trend similar to untreated and NGF
treated cells figure 3.12.
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Figure 3.12. Effect of Trichostatin A on HDAC activity in NS-1 cells. The NS-1 cell cultures
were treated with TSA (25 nM) and NGF (2.5 ng/mL) for 8, 24, 72 and 96 hours. The HDAC
activity (AFU) was measured in the lysates of treated and control NS-1 cell cultures following the
instructions in the protocol.
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3.2.6. Effect of vorinostat (suberoylanilide hydroxamic scid- SAHA) on neurite outgrowth
Vorinostat was evaluated for cytotoxicity against the NS-1 cells. The vorinostat
concentrations at 2.5 µM and 5μM were toxic (Figure 3.13) and the 1µM vorinostat was
completely safe for the NS-1 cells.
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Figure 3.13. Effect of vorinostat on growth and viability of NS-1 cells. Neuroscreen-1 cells
were treated with vorinostat for 72 hrs. At 48 hours, alamarBlue was added, viability was
measured at 72 hours using alamarBlue assay. Error bars shown are S.D. (Standard deviation) of
triplicate observations. .
In subsequent studies, NS-1 cells were treated with vorinostat (1 µM) and NGF (2.5 ng
mL-1) for 72 hours to investigate their neurotrophic actions Vorinostat (SAHA) at 1 µM
concentration, independent of NGF, stimulated significant neurite formation in NS-1 cells (Figure
3.14 A) compared to control cell culture. The neuritic outgrowth induced by vorinostat was
comparable to the effect of NGF.

The induction of neuritic out growth in NS-1 cells by

combination of vorinostat and NGF was similar to that produced by the NGF alone. Further, the
neurite outgrowth in NS-1 cells was quantitatively measured and presented as three end points
namely, mean neurite length (Figure 3.14 B), numbers of neurites/cell (Figure 3.14 C) and neurite
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length/cell (Figure 3.14 D). The independent and significant neurotrophic action of vorinostat was
confirmed based on significant increase in all three parameters, namely, mean neurite length,
numbers neurites/cell and neurite length/cell.

Neuritogenesis induced by vorinostat was

marginally less prominent as compared to NGF induced neuritogenesis. Vorinostat in combination
with NGF had a similar effect on neurite outgrowth as NGF treatment alone.
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Figure 3.14. Induction of neurite outgrowth in NS-1 cells by vorinostat treatment. [A]
Microscopic digital images of NS-1 cells (i) Control NS-1 cells (ii) NS-1 cells treated with 1 µM
vorinostat for 72 hrs. (iii) NS-1 cells treated with NGF (2.5 ng/ml) for 72 hrs (positive control).
(iv) NS-1 cells treated with vorinostat (1µM) + NGF (2.5 ng/mL). neurite outgrowth
/neuritogenesis significantly increased in vorinostat treated cells as indicated by three measured
parameters in terms of three end points namely, [B] mean neurite length [C] numbers of
neurites/cell and [D] neurite length/cell. Data represented are mean ± SD of three independent
experiments. * P< 0.05, compared to control.
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3.3. Aim 2: Interrogate cellular and molecular mechanisms of neurotrophic actions of
neurotrophic HDAC inhibitors
Neuritogenesis, the formation of neurites from a cell, is the initial step in the development
of a mature neuronal morphology (Craig and Banker, 1994). The key morphological features of
neuritogenesis include initial branching of neurites followed by elongation of axons and branching
of dendrites (Kiryushko et. al., 2004). Neuritogenesis is a key cellular process necessary for proper
development of the adult nervous and neuronal regeneration. Neurite extension from the soma
depends on precise cytoskeletal and adhesion dynamics induced by sensing of extracellular signals.
This process is similar to the directional pseudopodia formation involving regulated actinmediated membrane protrusion and signal transduction processes. Neurite outgrowth is a vital
event in neuronal development, formation and remodeling of synapses, response to injury, repair
and regeneration of damaged neurons. Understanding the mechanism of neurotrophic processes
like neurite outgrowth and neuronal survival is crucial for brain development studies and treatment
of various neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease (Jones
et. al., 2001).
Neurotrophic factors have been extensively studied with regard to their role in neuronal
development and synaptic plasticity. In in vitro and in vivo studies, neurotrophic factors have been
shown to promote neurite outgrowth, neuronal differentiation, proliferation, survival, and
regeneration. Neurotrophic factors are reported to increase the number and length of neurites
formed from the parent cell body of cultured neurons (Takano et. al., 2002). They also play an
important role in synapse formation during neurite outgrowth (Munno et. al., 2000) as well as for
synaptic plasticity (Schinder and Poo, 2000). Neurotrophic factors such as nerve growth factor
(NGF), brain derived nerve factors (BDNF), neurotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5)
64

are known to promote differentiation and survival of neurons via activation of tropomyosinreceptor-kinase (Trk) receptors namely, TrkA, TrkB and TrkC respectively. These receptors are
present on the cell membrane of neurons (Kaplan and Miller, 1997). Trk receptors are a family of
tyrosine kinases that regulate synaptic strength and plasticity in the mammalian nervous system.
Trk receptors affect neuronal survival and differentiation through several signal transduction
cascades. However, the activation of these receptors also has significant effects on functional
properties of neurons (Huang & Reichardt, 2003).
Signaling pathways linked to the process of neurite extension and survival are intricate,
involving complex signaling events. These signaling pathways mainly function through protein
phosphorylation cascades. Three of the pathways studied downstream of the Trk receptors are (I)
Ras/mitogen-activated protein kinase (MAPK) pathway, (II) Phosphatidylinositol-3 kinase
pathway (PI3-K) /AKT pathway, and (III) Phospholipase C-gamma 1 (PLCG1) pathway (Shimoke
et. al., 2009). The MAPK cascade is the most extensively characterized signaling pathway
controlling the neuritogenesis (Vaudry et.al, 2002). NGF-stimulated pathway has been the most
extensively investigated signaling mechanism for neuritic outgrowth (Figure 3.15). In initial
screening of several HDACi, vorinostat exhibited the most promising neurotrophic action.
Vorinostat independently induced significant neurite outgrowth in NS-1 cells, similar to that of
NGF. We further investigated the mechanism of vorinostat mediated neurite outgrowth by
interrogating the signaling pathways linked earlier to NGF-mediated neuritogenesis. It was
hypothesized that vorinostat stimulated neuritogenesis follows the mechanism similar to the NGFmediate signaling for neurite outgrowth. This hypothesis was verified by employing selective
inhibitors of the MAPK pathway (U0126 and PD98059), PI3K mediated signaling (Ly294002)

65

and TrkA (GW441756). The predicted role of cAMP-linked pathway was also investigated with
the SQ22536, a selective inhibitor of adenylate cyclase.
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Adopted from http://www.cellsignal.com/pathways

Figure 3.15- The NGF-linked TrkA mediated neurotrophin signaling pathway. Upon binding
of NGF to TrKA, Ras is activated which in turn activates c-Raf. Activation of MEK1 and MEK2
occurs through phosphorylation of two serine residues by Raf-like molecules. MEK1 and MEK2
are dual-specificity protein kinases that function in a mitogen activated protein kinase (MAPK)
cascade controlling cell growth and differentiation. Phosphoinositide 3-kinase and its downstream
effector kinase PKB/Akt are also activated by NGF playing role in neuronal survival.
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3.3.1. The vorinostat induced neuritogenesis in NS-1 cells may occur through activation of
ERK/MAPK pathway
For cytotoxicity & neuritogenesis assays 1000 cells/well were seeded onto collagen IV
coated 96 well plates in RPMI 1640 medium and incubated for 24 hrs at 37°C with 5% CO2. The
cell cultures were pretreated with the inhibitors of MEK1/2 (PD98059 or U0126) or PI3K
(LY294002) (10 µM) for 1 hour followed by treatment with vorinostat (1 µM) and/or NGF (2.5
ng/ml) (positive control). 0.025% of DMSO was used as a negative control. Cytotoxicity of these
inhibitors was measured at 72 hrs post-treatment and cells were further analyzed for neuritic
outgrowth by neuritogenesis assay as described in experimental section. Both the NGF- and
vorinostat-induced differentiation/neuritogenesis were significantly attenuated in the presence of
MEK inhibitors (PD98059 & U0126) as well as PI3K inhibitors (LY294002) (Figure 3.16 and
3.17). Neuritogenesis was measured in terms of mean neurite length (Figure 3.17.A), neurite
length/cell (Figure 3.17.B) and neurites/cell (Figure 3.17.C). However, the effect of LY294002
(PI3K inhibitor) was less prominent as compared to the MEK inhibitors on neurite outgrowth.
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Figure 3.16 The NS-1 cells treated with vorinostat (1µM), NGF (2.5ng/mL), PD98059, U0126
and LY294002 alone and combinations as indicated. Neurite outgrowth and cytoxicity were
measures as described in the experimental section and quantitative results are shown in Figure
3.17.
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Figure 3.17. Vorinostat induced neuritogenesis in NS-1 cells is dependent on activation of
MEK. NS-1 cells were treated with vorinostat (1µM), NGF (2.5 ng/mL), and/or inhibitors (10
µM) of MEK1/2 (PD98059 and U0126) and PI3K (LY294002) pathways for 72 hrs and assayed
for neurite outgrowth. The neurite outgrowth was measured as [A] Mean neurite length: ratio
between total neurites length and number of cells counted. [B] Neurites/cell: ratio between number
of neurites and number of cells counted and [C] neurite length/cell: ratio between total neurites
length and number of cells counted. The data sets are the mean ± SD of three independent
experiments. * P< 0.05, ** P< 0.001 and ns indicates non-significant difference compared to
control cells vs NGF and vorinostat and NGF and vorinostat treated cells vs inhibitor in
combination with vorinostat and NGF.
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3.3. 2. Vorinostat mediated phosphorylation of ERK is abolished in the presence of U0126,
an inhibitor of MAPK
Both vorinostat and NGF treatment produced a time-dependent activation of ERK (Figure
3.18.). NS-1 cells were treated with 1 µM vorinostat and 2.5 ng/mL NGF with and without U0126
for 5, 15, 30, 60 and 120 minutes. The cell lysates were subjected with SDS-PAGE and western
blot analysis and probed with anti-pERK antibodies. Vorinostat treatment produced prominent
activation of phosphorylation of ERK at 30 minutes, which increased further up to 2 hours posttreatment. The vorinostat mediated activiation of ERK was completely abolished in the presence
of U0126. NGF-mediated phosphorylation of ERK was rapid as early as 5 minutes and was also
attenuated in the presence of UO126 at all the time point tested. The results further confirm
neurotrophic actions of vorinostat through activation of the ERK signaling pathway.
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Figure 3.18. Effect of U0126 on vorinostat and NGF mediated ERK phosphorylation. NS-1 cells
were treated with vorinostat (1 μM) and NGF (2.5 ng/mL) with and without U0126 for 5, 15, 30,
60 and 120 minutes. The blots were probed with anti-pERK1/2 antibody. Vorinostat mediated
activation of ERK1/2 phosphorylation (pERK) was detected within 30 min after the treatment and
increased at 2 hrs. The vorinostat mediated ERK phosphorylation was completely abolished in the
presence of U0126. Similarly NGF mediated ERK phosphorylation was also reduced in the
presence of U0126 at all the time points. Total ERK levels were also checked. β-Actin was used
as loading control.
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3.3. 3. Vorinostat mediated activation of MEK-ERK1/2 signaling is dependent on TrKAmediated signaling
As vorinostat induced neurite outgrowth required activation of ERK, it was hypothesized
that it may involve activation of the upstream kinase (TrkA), like NGF-mediated neurite
outgrowth. To verify this hypothesis, vorinostat mediated neuritogenesis was investigated in the
presence or absence of GW441756 (1 µM), the inhibitor of TrkA. The NS-1 cell cultures were
pre-treated with GW441756 for 1 hour. Then vorinostat and NGF were added to the pretreated
cultures. (Figure 3. 19.) After 72 hrs treatment, cells were stained with Giemsa and neurite
outgrowth was measured with NIS element software. Endpoints measured were mean neurite
length (Figure 3. 19. A) and neurite length/cell (Figure 3. 19. B). There was a significant reduction
in neurite outgrowth measured in terms of mean neurite length and neurite length/cell in vorinostat
treated cells in presence of the TrkA inhibitor GW441756. In NS-1 cell cultures treated with
GW441756 and NGF a significant reduction in the neurite outgrowth was observed. These results
suggest that vorinostat mediated neuritogenesis involves activation of TrkA receptor similar to that
in case of NGF-mediated neurotrophic pathway.
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Figure 3.19. Vorinostat mediated neurite outgrowth in NS-1 cells was attenuated in presence
of TrkA inhibitor, GW441756. The vorinostat induced neuritogenesis in NS-1 cells was
dependent on activation of upstream kinase TrkA. NS-1 cells were pre-treated with GW441756
(Trki) (1µM) for 1 hour, followed by treatment with vorinostat (1 µM) or NGF (2.5 ng/mL), for
72 hrs and assayed for neurite outgrowth. The neurite outgrowth was measured as [A] Mean neurite
length: ratio between total neurites length and number of cells counted. [B] neurite length/cell:
ratio between total neurites length and number of cells counted. The data sets are the mean ± SD
of three independent experiments. * P< 0.05, ** P< 0.001 compared to control cells vs NGF and
vorinostat and NGF and vorinostat treated cells vs inhibitor in combination with vorinostat and
NGF.
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3.3. 4. Vorinostat mediated phosphorylation of ERK was attenuated in the presence of TrkA
inhibitor GW441756
As vorinostat mediated neurite outgrowth was attenuated in presence of TrkA inhibitor, we
further checked, whether activation of ERK phosphorylation induced by vorinostat was also
reduced in the presence of TrkA inhibitor. NS-1 cells (2.5x 105) were seeded onto collagen I coated
culture flasks and allowed to adhere for 24 hours. The cells were treated with vorinostat (1 µM
and 2.5 µM) with and without GW441756 for 3 hours. Cells were harvested, lysates ware prepared
and analyzed by SDS-PAGE Western blotting using antibody against anti-pERK. There was
significant activation of ERK at both the doses of vorinostat tested and this activation of ERK in
terms of ERK phosphorylation was completely abolished in the presence of GW44756 (Figure
3.20). The results clearly demonstrate the involvement of upstream kinase TrkA in vorinostat
mediated ERK phosphorylation and activation of neuritic outgrowth.
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Figure 3. 20. Effect of TrkA inhibitor on vorinostat mediated ERK phosphorylation. NS-1
cells were treated vorinostat (1 and 2.5 μM) with and without 1 μM GW441756 for 3 hours. The
lysates were analyzed by SDS-PAGE and blots were probed with anti pERK1/2 antibody.
Vorinostat mediated activation of ERK1/2 phosphorylation (pErk) was abolished in presence of
GW441756 (TrkA).

3.3. 5. Vorinostat induces hyperacetylation of histones H3 and H4
To determine whether changes in histone acetylation profile also occur during
differentiation of NS-1 cells and to verify that vorinostat was acting as an HDAC inhibitor in the
cells, we compared changes in acetylation of Histone H3 and H4 in untreated and vorinostat treated
cells (Figure 3.21.). To detect acetylation of histone H3 and H4, NS-1 cells were treated with
vorinostat (1 and 2.5 μM) for 24 hrs. Protein extracts were prepared from treated and untreated
cells and analysed by Western blot with antibodies specific for acetyl-histone H3 (Lys 9) and
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acetyl-Histone H4 (Lys 8). We observed hyperacetylation of histones H3 and H4 in vorinostat
treated NS-1 cells, while in untreated cells we did not detect any level of acetylation of histones
H3 and H4. The result suggests that there was significant hyperacetylation of H3 and H4 in
vorinostat treated cells. Increased in neuronal differentiation by vorinostat may be related to the
decrease in HDAC activity. To further confirm the effect of vorinostat treatment on histone
acetylation and deacetylation functions in NS-1 cells, the changes in acetylation of histones H3

Vorinostat 2.5µM

Vorinostat 1 µM

Control

and H4 were investigated. The steady state levels of histones were same in all samples.

Acetyl- H3
Histone H3
Acetyl- H4

Histone-H4

Figure 3.21. Effect of vorinostat on acetylation of histones H3 and H4. NS-1 cells treated with
vorinostat (1 and 2.5 μM) for 24 hrs. Western blotting was done and samples were probed with
acetyl H3 and H4 antibodies. Vorinostat (1 and 2.5 μM) doses induces hyperacetylation of
histones H3 and H4 at 24 hours Total histone H3 and H4 were also checked, which were unaltered.
3.3. 6. Vorinostat induces hyperacetylation of α-tubulin
To determine whether changes in acetylation of α-tubulin occur in vorinostat treated NS-1
cells during differentiation, we checked the acetylation of α-tubulin in the cells treated with
vorinostat for 8 hrs and 24 hrs. The cell extracts were subjected to SDS-PAGE and Western blot
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analysis and probed with antibodies against acetylated-α-tubulin (lys 40). Vorinostat, dosedependently produced hyperacetylation of α-tubulin at 8 hours as compared to untreated cells
(Figure 3.22.). However at 24 hour, hyperacetylation of α-tubulin was observed with 2.5 μM
vorinostat treatment, while at 1 μM no significant hyperacetylation of α-tubulin was observed.
Total tubulin levels were also checked. The level of total tubulin was unchanged in both treated
as well as untreated cells.

Vorinostat 2.5 μM

Vorinostat 1 μM

Control

24 hrs
Vorinostat 2.5 μM

Vorinostat 1 μM

Control

8 hrs

Acetyl-α Tubulin
Tubulin

Figure 3. 22. Effect of vorinostat on acetylation of α–tubulin. NS-1 cells treated with vorinostat
(1 and 2.5 μM) for 8 hrs and 24 hrs. Western blotting was done and samples were probed with
anti acetylated-α-Tubulin antibody. Vorinostat induced hyperacetylation of α-tubulin at 8 hrs and
24 hrs as compared to control. Total tubulin levels were also checked.
Further the effect of vorinostat on acetylation of tubulin was also evaluated in situ in NS1 cells. The NS-1 cells (1X105) were seeded onto an ibidi microchamber collagen IV coated 4
well plastic slide. The cells were allowed to adhere for 24 hrs and then treated with vorinostat (1
µM) or NGF (2.5 ng/mL) for 6 hours, and immunostained with a rabbit monoclonal antibody
against acetylated α-Tubulin (Lys40) (D20G3) XP®. NS-1 cells treated with vorinostat showed
increased levels of acetylated tubulin in the cytoplasm as compared to the untreated and NGF
treated cells (Figure 3.23). Results suggest that treatment with vorinostat leads to increase in
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acetylation
A Control

of

α-tubulin

in

B Vorinostat 1μM

NS-1

cells.

C NGF 2.5 ng/ml

Figure 3. 23. Immuno-localization of acetylated a-tubulin in NS-1 cells treated with
vorinostat and NGF. Treatment of NS-1 cells with vorinostat (1µM) for 6 hours resulted in
hyperacetylation of α-tubulin. A) Control cells with less staining for acetylalted α-tubulin (green)
B) Vorinostat treated cells with higher staining for acetyl α-tubulin (green) C) NGF treated cells
with less staining for acetyl α-tubulin. The cells were also stained with DAPI (blue color) for
localization of cell nucleus.

79

3.3. 7. Vorinostat treatment induces growth arrest in NS-1 cells: The cell cycle analysis.
For cell cycle analysis, the NS-1 cells (1×106) were serum starved for 18 hours before
treatment with vorinostat and NGF for 24 and 48 hours. The NS-1 cells were treated with
propidium iodide and analyzed by flow cytometry for cell cycle analysis. Treatment of NS-1 cells
with vorinostat resulted in significant decline in the percentages of cells in the S phase compared
with control cells, indicating the cell-cycle arrest by the vorinostat. While treatment of NS-1 cells
with vorinostat and NGF resulted in 50% decline in percentage of cell population at S phase as
compared to control cell at 24 hrs and 48 hours( Figure 3.24 A and B) and Figure (3.24 C and D).
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Figure 3. 24- Effect of vorinostat and NGF treatment after 24h on cell cycle of NS-1 cells as
analyzed by flowcytometry. Fig A shows a bar diagram for average % of NS-1 cells population
in each phase of the cell cycle at 24 hour. Figure B shows histograms of NS-1 cells population in
each phase of the cell cycle at 24 hour. The data sets are the mean ± SD of three independent
experiments. * P< 0.05 compared to control cells vs NGF and vorinostat.
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Figure 3. 24- Effect of vorinostat and NGF treatment after 48h on cell cycle of NS-1 cells as
analyzed by flowcytometry. Fig C shows a bar diagram for average % of NS-1 cells population
in each phase of the cell cycle at 48 hour. Figure D shows histograms of NS-1 cells population in
each phase of the cell cycle at 48 hour. The data sets are the mean ± SD of three independent
experiments. * P< 0.05 compared to control cells vs NGF and vorinostat.

3.3. 8. Effect of adenylate cyclase Inhibitor on vorinostat mediated neuritogenesis in NS-1
cells
In order to determine the role of cAMP pathway in vorinostat mediated neuritogenesis,
SQ22536, a selective inhibitor of adenylate cyclase was used. NS-1 cells were pretreated with
SQ22536 for 1 hour, followed by treatment with NGF (2.5 ng/mL) and vorinostat (1μM). DMSO
treated cells served as negative controls. At 72 hours, cytotoxicity was measured and then the cells
were stained by Giemsa to measure the neurite outgrowth. Intriguingly, vorinostat mediated
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neuritogenesis measured in terms of three parameters namely, (A) Mean neurite length, (B)
Number of neurites/cell and (C) Neurite length/cell was significantly potentiated in the presence
of the adenylate cyclase inhibitor(Figure 3. 25). However, NGF mediated neuritogenesis was not
significantly affected by the treatment with SQ22536.
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Figure 3. 25. Analysis of vorinostat mediated neurite outgrowth in the presence of adenylate
cyclase inhibitor (SQ22536). NS-1 cells were pre-treated with SQ22536 (200 µM) for 1 hour,
followed by treatment with vorinostat (1 µM) and NGF (2.5 ng/mL). The neurite outgrowth was
measured as. [A] Mean neurite length: ratio between total neurites length and number of cells
counted, [B] Number of neurites/cell and [C] Neurite length/cell: ratio between total neurites
length and number of cells counted. The data sets are mean±SD of three independent experiments.
* P< 0.05, ** P< 0.001 compared to control cells vs NGF and vorinostat and NGF and vorinostat
treated cells vs inhibitor in combination with vorinostat and NGF respectively. P values comparing
control vs SQ22536 and NGF vs NGF+SQ22536 were non-significant (ns).
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3.3. 9. Effect of belinostat and tenovin-1 on ERK phosphorylation
Vorinostat mediated neurite outgrowth involves activation of ERK.

Belinostat and

tenovin-1 did not induce neurite outgrowth; we hypothesized that belinostat and tenovin-1 would
not induce activation of ERK phosphorylation. The results presented in Figure 3.26 show that
belinostat (Figure 3.26A) and Tenovin-1 (Figure 3.26B) alone did not induce ERK
phosphorylation. However, there was significant increase in the level of phosphorylation in
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Figure 3.26. Effect of [A] belinostat and [B] tenovin-1 treatment on ERK phosphorylation.
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3.3. 10. Effect of HDAC inhibitors on acetylation of H3 and H4
The effect of other HDAC inhibitors screened for neurite outgrowth on acetylation of
histones H3 and H4 was also checked. NS-1 cells were treated with vorinostat (1 and 2.5 μM),
belinostat (0.25 and 0.5 μM), tubastatin-A (5 and 10 μM), PCI-34051 (5 μM) and tenovin-1 (10
μM) for 24 hours. Vorinostat, belinostat, and tubastatin-A induced hyperacetylation of histones
H3 and H4. However, PCI-34051 and tenovin-1 did not induce hyperacetylation of H3 and H4.
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Tubastatin 10 µM

Tubastatin 5 µm
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Belinosat 0.25 µM

Vorinostat 2.5 µm

Vorinostat 1µM
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(Figure 3.27.). The steady state level of histones H3 and H4 remained unchanged.

Acetyl H3
Total H3
Acetyl H4
Total H4

Figure 3.27. Effect of treatment with HDAC inhibitors on acetylation Histone H3 and H4 in NS1 cells.
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3.3. 11. Effect of HDAC inhibitors on acetylation of α-tubulin
The HDAC inhibitors screened for neurite outgrowth were also evaluated for the effect on
acetylation of α-tubulin in NS-1 cells. The NS-1 cells were treated with vorinostat (1 and 2.5 μM),
belinostat (0.25 and 0.5 μM), tubastatin-A (5 and 10 μM), PCI-34051 (5 μM) and tenovin-1 (10
μM) for 24 hours. Tubastatin-A induced hyperacetylation of α-tubulin in NS-1 cells. However,
belinostat, PCI-34051 and tenovin-1 did not induce hyperacetylation of α-tubulin in NS-1 cells.
Vorinostat treatment produced significant hyperacetylation of α-tubulin at 8 hours as reported in
previous experiments (Figure 3.22); however, longer 24 hours treatment did not produce much
hyperacetylation of -tubulin. Further, none of these treatments produced significant change in
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Tubastatin 10 µM

Tubastatin 5 µM
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Belinosat 0.25 µM
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steady state levels of -tubulin (Figure 3.28.).

Acetylated α- Tubulin
Total tubulin

Figure 3. 28. Effect of HDAC inhibitors on acetylation of α-tubulin in NS-1 cells.
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CHAPTER 4
DISCUSSION
Neuritogenesis, formation of neurites by neuronal cells, is the initial step in the
development of a mature neuronal morphology (Dotti et. al., 1988; Craig and Banker, 1994). The
key morphological features of neuritogenesis include branching of neurites followed by elongation
of axons and branching of dendrites (Kiryushko et. al., 2004). Neurite outgrowth is a vital event
in neuronal development. It also plays an important role in formation, and remodeling of synapses,
response to injury, and regeneration.

Thus, understanding the mechanism of neurotrophic

processes like neurite outgrowth and neuronal survival is crucial for studies related to brain
development, pathophysiology and treatment of various neurodegenerative disorders like
Alzheimer’s and Parkinson’s diseases (Kaplan and Miller, 1997).
Neurotrophic factors have been extensively studied with regard to their role in neuronal
development and synaptic plasticity. In in vivo and in vitro studies, neurotrophic factors have been
shown to promote neurite outgrowth, neuronal differentiation, proliferation, survival, and
regeneration (Takano et.al, 2002; Munno et.al, 2000; Schinder et.al, 2000). However, as treatment
modalities, neurotrophic factors are large polypeptide molecules and have limited permeability
across the blood brain barrier. Also, they are easily metabolized by peptidases, which pose the
greatest barrier for their therapeutic application (Maruoka et.al, 2011). Therefore, the small
molecule neurotrophic compounds that can mimic the functions of intrinsic neurotrophic factors
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could serve as good alternates for therapeutic use in treatment of neurodegenerative diseases and
neuronal injuries (More et. al., 2012; Longo and Massa, 2013).
Recent reports have demonstrated neuroprotective and neuroactive properties of small
molecular weight inhibitors of histone deacetylases (HDACs) and their potential use in treatment
of neurological disorders (Camelo et. al, 2005; Wiech et. al, 2009; Xu et. al, 2011). HDACs
catalyze the removal of acetyl groups from histones and non-histone proteins and are major
epigenetic regulators (Hildmann et. al, 2007).

Within the last decade, many studies have

demonstrated neuroprotective effects of HDAC inhibitors (HDACi) (Chuang et. al, 2009). HDACi
are recognized as potential anticancer agents (Slingerland et. al, 2014; Bose et. al, 2014) and also
play important role in inducing neurite outgrowth and neuroprotection (Xu et. al, 2011). In
diseased neurons, HDACi, by reducing histone deacetylation, can restore transcriptional balance
and thereby delay or stop cellular degeneration. It is considered that neurotrophic activities of
HDACi may be epigenetically controlled by acetylation of histones as well as non-histone proteins
such as transcription factors (Sterner and Berger, 2000). During neuronal development in the
peripheral nervous system, regulation of transcription by epigenetic modifications has been
reported to play an important role in neurite outgrowth and neuroprotection (Guab et. al, 2010).
Evidence for a neuroprotective role of HDACi has been developed in experimental models of
various neurodegenerative diseases such as Huntington Disease (Gardian et. al, 2005),
amyotrophic lateral sclerosis (Petri et. al, 2006), and multiple sclerosis (Camelo et. al, 2005).
However, the precise mechanisms of the neuroprotection are not clearly understood.
In a recent comprehensive study with monoaminergic and neuropeptidergic neurons the
global expression and localization of the HDAC protein family from HDAC1 to HDAC11 was
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studied in corticotropin-releasing hormone, oxytocin, vasopressin, agouti-related peptide (AgRP),
pro-opiomelanocortin (POMC), orexin, histamine, dopamine, serotonin, and noradrenaline
neurons (Takase et. al., 2013). The study indicated the differential expression of HDACs in
monoaminergic and neuropeptidergic neurons, which may be crucial for the maintenance of
biological characteristics of the specific neurons and their differential response to physiological
and environmental factors (Takase et. al., 2013). Considering the possible neuroprotective and
neurotrophic role of the HDACi, the primary aim of this study was to examine the potential of
HDACi in modulating neuritogenesis in NS-1 cells, and to interrogate the underlying cellular and
molecular mechanisms involved.
4.1 Differential neurotrophic responses of pan and isoform selective HDACi
The pan HDACi namely, vorinostat, TSA and belinostat as well as isoform specific
inhibitors namely, PCI-34051 (HDAC8) and tubastatin A (HDAC6), tenovin-1 (SirT1&2) were
tested for their effects in vitro on the neurite outgrowth in NS-1 cells to ascertain the roles of
HDACs in the process of neurite outgrowth. Evaluation of as isoform specific inhibitor would
lead to the determination of target-specific functions of HDAC isoforms in the neuritogenesis
process. Differential responses of individual HDACi on direct and NGF-stimulated neurite
outgrowth indicate variable functions of different HDAC isoforms in this process. Among the
battery of HDACi tested alone and in combination with NGF, vorinostat exhibited the most
prominent independent neurotrophic action on NS-1 cells. Qualitatively and quantitatively the
neurotrophic action of vorinostat was similar to the NGF. The NGF is neurotrophin and a cytokine,
which is mainly produced and secreted by hypothalamus, pituitary glands and also several other
tissues as well as cell types (McAllister, 2001). Impairments of NGF production and functions
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have been implicated in several neuronal and non-neuronal disorders. The most prominent clinical
significance of NGF has been in the prevention of neurodegeneration and also in neuroregeneration
(Allen and Dawbarn, 2006). Other hydroxamic acid HDACi tested in our study namely, TSA and
belinostat exhibited different responses compared to vorinostat regarding the effect on the neurite
outgrowth in NS-1 cells. TSA at all doses did not induce noticeable neurite outgrowth in NS-1
cells. However, previous studies have reported contrasting results regarding neurotropic potential
of TSA. TSA promoted neurogenesis, neurite outgrowth, synaptic plasticity and neuroprotection
in primary rat cortical neurons following ischemic insult (Hasan et. al., 2013). Treatment with
TSA increased neurite length in rat cultured cerebellar granule neurons and in cerebral cortical
neurons presumably through acetylation of p53 (Maruoka et. al., 2011). TSA was also found to
induce neurite outgrowth in PC12 cells by expression of early gene IEG nur77. The induction of
neurite outgrowth in PC12 cells was prevented with C646, an inhibitor of HAT (histone acetyl
transferase) (Tomioka et. al, 2014). However, a study by Futamura et. al., (1995) has shown that,
TSA inhibited NGF mediated neuritogenesis by blocking both oncogenic ras and NGF mediated
neuritogenesis. However, adding TSA one hour after addition of NGF did not inhibit the NGF
mediated neuritogenesis, suggesting that TSA affected the early gene expression in NGF-induced
neuritogenesis by promoting histone deacetylation. Wang et. al., (2009) reported that TSA
treatment resulted in decreased survival and increased apoptosis in dopaminergic neuronal cells
like N27, MN9D and human SH-SY5Y cells. Our results show that belinostat, a p53 activator and
an HDACi belonging to the hydroxamic acid class, did not induce neurite outgrowth in NS-1 cells
by itself; however, intriguingly it significantly attenuated the NGF-mediated neuritogenesis when
the cells were co-treated with belinostat and NGF. The results suggest that belinostat might inhibit
ras mediated neurite outgrowth induced by NGF, as reported earlier for TSA mediated inhibition
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in neuite outgrowth in PC12 cells (Futamura et. al., 1995). These contrasting effects of HDACi
may be attributed to varying epigenetic status, cell type and tissue specificity. The non-selective
HDAC inhibition by TSA and belinostat may be contributing to contradictory effects of the
HDACi observed in different cell types.
The isoform specific HDACi PCI-34051, a selective HDAC8 inhibitor, did not affect the
viability up to 10 M concentrations and increased the neurite outgrowth in NS-1 cells at 5 μM.
In a study with two neuroblastoma cell lines, BE (2)-C and Kelly, PCI-34051 did not affect the
viability of the cells and did not induce the differentiation of neuroblastoma cells (Frumm et. al,
2014). A recent immunolocalization study reported presence of high levels of HDAC8 in the
cytoplasm of histamine neurons with a pericellular pattern but not in other neuropeptidergic and
monoaminergic neurons (Takase et. al, 2013). NBM-T-L-BMX-OS01 (BMX), derived from the
semisynthesis of osthole, isolated from Cnidium monnieri (L.) Cuss., and a potent inhibitor of
HDAC8 has been shown to enhance neurite outgrowth and cAMP response element-binding
protein (CREB) activation and also improved neural plasticity, learning and memory in rats ( Yang
et. al.,2013).
A previous study with dorsal root ganglion neurons has shown that inhibiting HDAC6
protected against neuronal degeneration and stimulated neurite outgrowth (Rivieccio et. al., 2009).
Tubastatin-A at 5 μM significantly increased the neurites/cells, however no increase in other end
points was measured i.e neurite length/cell and mean neurite length in NS-1 cells at this dose or
any other doses tested. Co-treatment of tubastatin-A and NGF produced a significant increase in
neurite outgrowth measured in terms of three parameters. The neurite outgrowth in NGF and
tubastatin-A co-treated samples was similar to the NS-1 cells treated with NGF alone. Quinazolin92

4-one derivatives containing a hydroxamic acid moiety, identified as selective and potent HDAC6
inhibitors, were found to induce neurite outgrowth in PC12 and SH-SY5Y neuronal cells without
producing toxic or mitogenic effects (Yu et. al., 2013). Further, the analogs also caused an increase
in acetylation of non-histone protein, -tubulin. A Tetrahydroisoquinoline analogs, identified as
a dual HDAC6 and HDAC8 inhibitors, produced elevated levels of acetylated tubulin, TrkA, and
neurite outgrowth in neuroblastoma BE (2)C cells (Tang et. al., 2014).
Contrasting reports have also been made regarding functions and role of sirtiuns, the NAD+
dependent HDACs in neuritic outgrowth and neuronal differentiation. Sirtuins play important role
in maintaining the neuronal health, especially during the conditions leading to neurodegeneration
and aging (de Oliveira et. al., 2010; Donmez, 2012) SIRT1, a sirtuin HDAC, has been shown to
play important role in axonal elongation, neurite outgrowth, dendritic branching and memory
formation by modulating synaptic plasticity (Herskovits and Guarente, 2014). Expression of
SIRT1 has been confirmed in the cytoplasm of PC12 cells. Activators of SIRT1 promoted the
NGF-induced neurite outgrowth of PC12 cells, while SIRT1 inhibitors or SIRT1-siRNA
significantly inhibited it. The overexpression of a mutant SIRT1 that localized to the cytoplasm
but not the nucleus enhanced the NGF-dependent neurite outgrowth, while a cytoplasmic
dominant-negative SIRT1 suppressed it. These experiments concluded that cytoplasmic SIRT1
potentiated the NGF-induced neurite outgrowth of PC12 cells (Sugino et. al., 2010).
Contrastingly, differentiation and maturation of embryonic cortical neurons and N2a
neuroprogenitor cells was reported to be associated with decreases in SIRT1 expression (Liu et.
al., 2014).
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This was further confirmed by the observation that shRNA-mediated knock down of SIRT1
resulted in induction of neurite outgrowth, whereas overexpression of SIRT1 attenuated the neural
differentiation in N2a cells. Tenovin-1, the SirT1 and SirT2 inhibitors, attenuated the NGFstimulated neurite outgrowth in NS-1 cells confirming the role of sirtuins in neuronal
differentiation as reported earlier.
In conclusion, the results reported here again implicate varying responses of the HDACi
and differential roles of different HDACs in different cell types regarding their role in
differentiation of neuronal cells. Among the battery of HDACi tested vorinostat was the only
HDACi which showed the most prominent neurotrophic action. The neurotrophic action of
vorinostat was independent of NGF. Other HDACi tested showed relatively marginal and variable
effects on the neuritic outgrowth in the NS-1 cells.
4.2. Pathways and mechanisms for neurotrophic actions of HDACi
Neurotrophic actions enhance neuroplasticity and neurite outgrowth, which are important
markers for neuroregeneration, neuronal differentiation and repair of neuronal injuries (Akagi et.
al, 2015). These processes are regulated by extrinsic and intrinsic determinants that affect gene
expression and signal transduction pathways (Nakamura et. al., 2008). Recent studies have
reported neuroprotective effects of the HDACi. The HDACs regulate expression of genes through
deacetylation of histones and activation of transcription. The results presented here show that
vorinostat induced neuritogenesis in NS-1 cells. Attenuation of neurite outgrowth in presence of
MEK1/2 inhibitor, U0126 suggests the involvement of the ERK pathway in vorinostat-induced
differentiation of the NS-1 cells. Mitigation of ERK phosphorylation mediated by vorinostat in
presence of U0126 further confirms the involvement of MAPK pathway.
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The potential

involvement of the PI3K pathway was also tested. Although neuritogenesis induced by vorinostat
was attenuated in presence of PI3K inhibitor (LY294002). However, the attenuation of vorinostatinduced neuritogenesis by the PI3K inhibitor was partial and less prominent as compared to the
ERK inhibitors, U0126 and PD98059. Studies with inhibitors of TrkA (Tyrosine Kinase A) in
vorinostat treated cells attenuated the neurite outgrowth and also reduced the phosphorylation of
ERK. This suggested role of activation of upstream kinase TrkA, the neurotrophin receptor, in the
process of vorinostat mediated neurite outgrowth and activation of MAPK pathway. However,
the mechanism for activation of TrkA by vorinostat was still not clear. Vorinostat also induced
hyperacetylation of histones H3 and H4 in NS-1 cells, which suggested histone acetylation plays
as important role in the induction of neurite outgrowth. The results are in agreement with the other
reports, where increases in acetylation of histones and transcription factors in neurons have been
shown to promote the differentiation of neurons, whose molecular mechanisms are to some extent
shared at some point in neurite outgrowth. Hyperacetylation of histone H3 and H4 has been
correlated with the plasticity of neuron and developmental process (Guab et. al., 2010). Vorinostat
also induced hyperacetylation of α-tubulin in NS-1 cells, hyperacetylation of α-tubulin is important
for microtubule stabilization and transportation (Hubbert et. al., 2002). Hyperacetylation of αtubulin occurs due to pharmacological inhibition of HDAC6 that leads to increased acetylation of
α-tubulin (Zhang et.al, 2003). HDAC class I and HDAC6 also could directly regulate neurite
growth independently of epigenetic effects on transcription through deacetylation of α-tubulin and
other proteins (Hubbert et. al., 2002; Rivieccio et. al., 2009). Vorinostat mediated hyperacetylation
of α-tubulin demonstrates the importance of acetylation of tubulin in the process of neurite
outgrowth. Tubastatin-A also induced hyperacetylation of α-tubulin in NS-1 cells; however, its
response in terms of neurite outgrowth was not similar to vorinostat, suggesting that other factors
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also influence the neurite outgrowth. Neurotrophin-mediated activation of TrkA receptor leads to
activation of selected complex sets of signaling pathways (Patapoutian and Reichardt, 2001),
which involve large number of signaling events associated with neurite extension/differentiation
and neuroprotection. These signaling pathways mainly function through phosphorylation of select
sets of kinases. Three major neurotrophin signaling pathways are (I) Ras/mitogen-activated
protein kinase (MAPK) pathway, (II) Phosphatidylinositol-3 kinase pathway (PI3-K)/AKT
pathway, and (III) Phospholipase C (PLC)- pathway (Shimoke et.al., 2009). The MAPK cascade
is the most implicated pathway in controlling neuritogenesis/differentiation of neuronal cells
(Kaplan and Miller, 1997). Ras-extracellular signal regulated kinase (RAS-ERK) pathway also
plays important role in neuronal differentiation (Enarson et. al, 2002). Activation of small
GTPase, Ras through neurotrophin leads to signaling and transcription regulation, and plays an
important role in neuronal survival and differentiation (Moodie et. al., 1993). Activation of Ras
leads to downstream activation of Raf1 and B-Raf, which in turn activates mitogen activated
protein kinases MEK1 and MEK2, which further lead to phosphorylation of another set of MAP
kinases, ERK1 and ERK2. MEK1 and MEK2 are dual-specificity protein kinases that function in
the mitogen activated protein kinase (MAPK) cascade. The ERK signaling pathway controls cell
growth, proliferation, differentiation and cell survival. The NGF-induced neuritogenesis in PC12
cells occurs via sustained activation of extracellular signal regulated kinase through activation of
TrkA (Marshall 1998; Rak-hit et. al., 2001; Vaudry et. al., 2002). NGF also activates PI3K and
downstream effector kinase PKB/Akt, playing a role in neuronal survival. The study was
performed to assess the mechanism of vorinostat-induced neurite outgrowth, the activation of ERK
pathway given its accepted role in cellular differentiation (Enarson et. al, 2002). As vorinostat
independently induced neuritogenesis in NS-1 cells like NGF, it is hypothesized that vorinostat96

mediated differentiation in NS-1 cells might occur via activation of ERK and/or PI3K pathways,
similar to the activation by NGF. Both TrkA-associated pathways, namely MEK/MAPK and
PI3K, were interrogated for vorinostat-induced neuritic outgrowth. This result suggested that
vorinostat promotes neuritogenesis in NS-1 cells via activation of the ERK pathway. Blockade of
vorinostat–induced differentiation measured in terms of mean neurite length, neurites/cell and
neurite length/cell by PD98059 and U0126 indicates that activation of ERK by MEK is required
for this effect. Treatment of NS-1 cells with vorinostat also activated phosphorylation of ERK.
Vorinostat mediated neuritogenesis as well as activation of ERK was attenuated by TrkA inhibitor
suggesting the involvement of TrkA receptor in the activation of ERK pathway by vorinostat. The
mechanism by which vorinostat brings about differentiation and neuritogenesis in NS-1 cells may
be through binding and activation of relevant neurotrophin receptor (Chen et. al., 2012). However,
other associated signaling events and the precise mechanism for activation of ERK by vorinostat
should be examined further. Vorinostat, as an anticancer agent in epidermal squamous cell
carcinoma, reduced cell survival by a reduction in mTOR pathway and ERK signaling pathway
(Deepali et. al, 2009). However, in a different study, vorinostat treatment in lymphoplasmacytic
cells in waldenstrom macroglobulinemia led to apoptosis by affecting MAPK pathways (Jenny et.
al, 2011). The phospho-extracellular signal regulated kinase was abruptly decreased at 24 hours,
while phospho 38 MAPK was up regulated at 12 hours in Lymphoplasmacytic cells (Jenny et. al.,
2011). These reports indicate that the MAPK/ERK pathways show varying response to vorinostat
depending on the target cells.
The Valproic acid (VPA), an HDACi used as an anticonvulsant and mood-stabilizing drug
for treatment of epilepsy, bipolar disorder and prevention of migraine headaches, has been shown
to be neuroprotective in primary astroglial cultures. VPA induced the expression of GDNF and
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BDNF, which in turn activated the ERK pathway in primary astroglial cultures (Chen et. al., 2006).
Yuan et. al., (2001) reported that VPA stimulated neurite outgrowth in SH-SY5Y cell culture by
activation of ERK pathway. These actions of VPA were similar to the effects exerted by the
neurotrophic factors. The neurotrophic and neuroprotective effect of VPA, such as neuronal
survival, neurite outgrowth and neurogenesis involve multiple mechanisms. VPA is also known
to modulate the activity of several intracellular enzymes, including mitogen-activated protein
kinases (MAPKs), protein kinase C (PKC) and glycogen synthase kinase-3β (GSK-3β)
(Kostrouchova et.al, 2007). Apart from HDAC inhibition and histone hyperacetylation, activation
of ERK pathway (Hao et. al., 2004; Yuan et. al., 2001), microglial–mediated inflammation (Peng
et. al., 2005) and inhibition of pro-apoptotic factors (Kim et. al., 2007) have also been reported
earlier for VPA. The results presented support the hypothesis that neurotrophic activity of
vorinostat is mediated through activation of ERK pathway, histone hyperacetylation and
acetylation of non–histone proteins like α-tubulin. HDACi have shown significant impacts on
neuronal, cardiomyocytic, and hepatic lineage differentiations. In most of the cases molecular
mechanism for induction of differentiation have been linked to regulation of transcription factors
(Gaub et. al., 2010). In experimental models of disease such as, amylotrophic lateral sclerosis,
multiple sclerosis and Huntington’s disease, neuroprotective effects of HDACi have been noted.
However, precise mechanisms for their neuroprotection action are still obscure. Activation of the
ERK pathway via TrkA receptor seems to be one of the mechanisms for induction of
neuritogenesis by vorinostat in NS-1 cells. In contrast to the more rapid induction of ERK
phosphorylation by NGF, vorinostat-induced phosphorylation of ERK was delayed, and was
relatively transient and more stable. These observations imply that vorinostat may be readily
inactivated, or perhaps the mechanism of ERK activation by vorinostat is different from that of
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NGF. Vorinostat-induced neurite outgrowth appears to involve not only MEK, but also PI3K,
since the neuritogenesis was inhibited in presence of LY294002, a PI3K inhibitor. As the
differentiation of cells is typically associated with a cell cycle arrest, we also analyzed the effects
of vorinostat on cell cycle of NS-1 cells. The flow cytometer analysis results for cell cycle studies
in vorinostat and NGF treated NS-1 cells showed significant decline in percentage of cells in S
phase at 24 and 48 hours post treatment, suggesting that the major population of cells were arrested
in differentiation stage. Neuroendocrine cells have been shown to differentiate in presence of
ligands that activate G protein coupled receptors, which in turn increase the level of cAMP.
Previous reports have also suggested important role of cAMP in NGF-mediated neuritogenesis.
Chen et. al., (2010) have shown, using molecular pathway inhibitors, that cAMP played a role in
activation of p35/Cdk5 and this regulation was an important pathway for NGF-mediated
differentiation of PC12 cells. A recent contrasting report by Emery et. al., (2014) showed that
NGF-mediated differentiation of PC12 and NS-1 cells did not require cAMP sensors protein kinase
A, Epac, or neuritogenic cyclic AMP sensor/Rapgef2. The NGF-mediated signaling rather
involved ERK and p38 activation through a cAMP independent pathway. The cAMP cascade has
also been shown to have as important role in neuronal survival, plasticity, and differentiation
(Nakagawa et. al, 2002). It is also investigated the involvement of cAMP pathway in vorinostat
mediated neurite outgrowth.

Surprisingly, adenlyate cyclase inhibitor SQ22536 further

potentiated the neurite outgrowth induced by vorinostat. These results suggested that the signaling
pathway(s) for vorinostat mediated neuritogenesis may be different from NGF-mediated signaling
mechanisms as NGF-mediated neurite outgrowth was not affected in presence of adenylate cyclase
inhibitor SQ22536. It would be important to investigate the possible role of other converging
kinases, such as the cAMP and PKA-dependent pathway, in the downstream neuritogenic
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pathways or the pathways independent of MAPK/ERK activation. It would also be interesting to
assess transcription dependent effect of vorinostat on NS-1 cell differentiation and regulation of
expression of genes linked to the pathways of neuronal differentiation, neuritogenesis and
neuroprotection. This study establishes neurotrophic potential of vorinostat, and partly elucidates
cellular and molecular mechanisms for vorinostat-mediated neurite outgrowth in NS-1 cells.
Vorinostat induced neuritogenesis appears to involve activation of ERK pathways through TrkA
receptor.

Vorinostat induces hyperacetylation of α-tubulin which plays important role in

neuriteoutgrowth /differentiation process. Hyperacetylation of histones H3 and H4 by vorinostat
in NS-1 cells suggest significant role of transcription regulation of genes related to differentiation.
Vorinostat is permeable to the blood brain barrier (Grant 2007; Lemonie& Younes, 2010), which
makes it an important drug candidate for targeting central nervous system. Vorinostat and other
related HDACi with neurotrophic actions may be evaluated as promising candidates and potential
therapeutic agents for treatment of neurodegenerative diseases and neuronal injuries by virtue of
their ability to stimulate neuritic outgrowth.
Belinostat, also a pan HDACi, shows a completely different response in terms of neurite
outgrowth as compared to vorinostat in NS-1 cells. Belinostat did not induce neurite outgrowth
by itself and it attenuated the neurite outgrowth induced by NGF. Belinostat did not induce ERK
phosphorylation by itself however, but it further increased the phosphorylation of ERK in presence
of NGF. These results suggest that other factors may be involved in attenuation neurotrophic
action of NGF by belinostat. Belinostat (0.5M) induced hyperacetylation of histones H3 and H4
similar to that by vorinostat.
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Tenovin-1, a sirtunin (SirT1 and SirT2) inhibitor, also inhibited NGF-mediated neurite
outgrowth. Tenovin-1 did not affect phosphorylation of ERK dependently and also did not induce
hyperacetylation of histones H3 and H4.
Vorinostat and tubastatin-A both caused hyperacetylation of α-tubulin in NS-1 cells.
However, their response in terms of neurite outgrowth was different. Vorinostat significantly
induced neurite outgrowth in all the three parameters tested, but tubastain-A induced neurites/cell
but not neurite length/cell or mean neurite length. Tubastatin-A is a selective HDAC6 inhibitor
and vorinostat also inhibits HDAC6. This suggests that additional on-target as well as off-target
effects of HDACi other than inhibition of HDAC6 may be important in the process of
neuritogenesis.
To the best of our knowledge, this is the first study showing role of the ERK pathway and
upstream kinase TrkA in Vorinostat-induced neurite outgrowth in NS-1 cells. This finding is in
agreement with a number of previous studies, which have shown that HDACi exert
neuroprotective & neuritogenic effects via activation ERK pathways (Hao et. al., 2004; Hsieh et.
al., 2004). Treatment of NS-1 cells with vorinostat and inhibitors of adenylate cyclase increased
the neurite outgrowth in NS-1 cells suggesting the role of other pathways and factors in inducing
vorinostat mediated differentiation of NS-1.
These observations imply that differentiation is a process that occurs through the
simultaneous activation of multiple parallel signaling events rather than a single master pathway
(Ravni et. al., 2008). It would be important to investigate the possible role of other converging
kinases, such as the cAMP and PKA-dependent pathway in detail, in the downstream neuritogenic
pathways or the pathways independent of MAPK/ERK activation. It would also be interesting to
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assess transcription dependent effect of Vorinostat on NS-1 cell differentiation and regulation of
expression of genes linked to the pathways of neuronal differentiation, neuritogenesis and
neuroprotection.
This study demonstrates a neurotrophic effect of vorinostat, and elucidates cellular and
molecular mechanisms for Vorinostat-mediated neurite outgrowth in NS-1 cells. Vorinostat
induced neuritogenesis appears to involve activation of ERK pathways through activation of TrkA
receptor. Vorinostat also induces hyperacetylation of α-tubulin which plays important role in
neurite outgrowth /differentiation process. Hyperacetylation of histones H3 and H4 by vorinostat
in NS-1 cells suggest significant role of transcription regulation of genes related to differentiation.
Vorinostat is permeable to the blood brain barrier (Grant, 2007; Lemonie&Younes, 2010), which
makes it an important drug candidate for targeting central nervous system. Other pan, selective
and isoform specific HDACi tested had variable results in terms of neurite outgrowth in NS-1
cells. Detailed study of these inhibitors vis-à-vis their mechanism of actions are required to
ascertain the role of each HDAC inhibitors in the process of differentiation and to know what
causes the variable response of HDACi in NS-1 cells.
Vorinostat and other related HDACi with neurotrophic actions could be a promising
candidates and potential therapeutic agents for treatment of neurodegenerative diseases and
neuronal injuries by virtue of their ability to stimulate neuritic outgrowth.
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SUMMARY AND CONCLUSION
The neurodegenerative disease like Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease and Amyotrophic lateral sclerosis are primarily characterized by progressive
loss and death of neurons due to their diminished structure and functions.

Progressive

neurodegeneration occurs as a part of normal aging process. The traumatic brain and spinal cord
nerve injuries also cause loss of functions of neurons.

The drugs capable of stimulating

neuroregeneration and induction of neuritic growth may reverse the loss of neuronal functions due
to neurodegenerative diseases and nerve injuries. Neurite outgrowth is a fundamental process in
differentiation of neurons, which plays a critical role in formation of new neurons, remodeling of
synapse, repair of damaged neurons and regeneration of neurons. The neurotrophic factors,
commonly referred as neurotrophins are proteinaceous factors, which are important for survival,
maintenance and development of central and peripheral nervous systems. Preclinical studies point
to the therapeutic potential of neurotrophic factors in preventing or slowing the progression of
neurodegenerative conditions by repair and restoration of normal neuronal function of the
damaged neurons. However, owing to the inherent difficulties with a protein therapeutic approach
for treating central nervous system disorders, increasing attention has turned to the development
of alternative strategies and, in particular, small molecule mimetic. The inhibitors of histone
deacetylases (HDAC) being small molecule inhibitors and many of them having ability to cross
the blood brain barrier offer important leads for their evaluation as potential neurotrophic agents.
HDACs are the components of process of reversible acetylation/deacetylation of histones and
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several non-histone proteins and are known to play important role in transcriptional regulation and
gene expression. Reports have indicated important role of HDACi in the process of neurite
outgrowth, neuronal differentiation and neuroprotection. Therefore, the HDACi may be the
potential drug leads for treatment of neurodegenerative diseases. In view of this, a battery of
HDACi were evaluated as potential neurotrophins. The lead HDACi with promising neurotrophic
action was further evaluated to understand the mechanism of their action.
Evaluation of HDACi as potential neurotrophic agents and understanding the mechanism of
their actions
Eleven isoforms of HDACs have been broadly divided into three classes based on their
sequence homology and comparative domain structures. Another unrelated class of HDACs,
referred as sirtiuns, contains additional 7 isoforms. A set of pan and isoform specific HDACi were
selected and evaluated in vitro on NeuroScreen-1 (NS-1) cell line, which is a clone of PC12 cells
derived from a pheochromocytoma of the rat adrenal medulla. The PC12 cells, when treated with
nerve growth factor (NGF), an indigenous neurotrophin, induces neurite outgrowth and creates the
cells with morphology like growing neurons.

This model has been used extensively for

understanding the mechanisms of neurotrophin actions, neuritogenesis and neurosecretion.
A combined in vitro method was standardized with NS-1 cells that measures and quantifies
neurite outgrowth along with the cell viability (cytotoxicity of the test compounds) in a single
assay. The stimulation of neurite outgrowth was measured by analysis of digital cell images by
the NIS software in terms of multiple parameters namely, the effect of test compounds on mean
neurite length, neurite length/cell, nodes/cell and number of neurites/cells.
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Out of the several HDAC inhibitors tested for their effects on neurite outgrowth in NS-1
cells, vorinostat, a pan HDAC inhibitor, significantly induced neurite outgrowth. The independent
neurotrophic action of vorinostat was similar to that induced by NGF. Vorinostat is currently
under clinical use for treatment of cutaneous T cell lymphoma (CTCL). The inhibitors of
neurotrophin molecular signaling pathway namely U0126, PD98059 (the inhibitors of MAP
kinases MEK1/MEK2) and LY294002 (the PI3K inhibitor) were employed to understand the
mechanism for neurotrophic actions of vorinostat. These inhibitors significantly attenuated the
vorinostat mediated neurite outgrowth in NS-1 cells, and also reduced the level of ERK
phosphorylation. These results implicated that vorinostat induced neuritogenesis occurs through
activation of ERK and PI3K signaling pathways, which is similar to that reported for NGF. The
role of upstream neurotrophin receptor kinase TrkA was also studied in vorinostat induced neurite
outgrowth using a TrkA inhibitor, GW441756. The vorinostat mediated neurite outgrowth was
reduced in presence of TrkA inhibitor. GW441756 also abolished vorinostat mediated ERK
phosphorylation/activation, suggesting the role of upstream kinase TrkA in the vorinostat mediated
neurite outgrowth and activation of ERK.
The neurotrophin signaling has been shown to involve cAMP downstream in the pathways.
SQ22536, a selective inhibitor of adenylate cyclase, was tested on vorinostat-induced neurite
outgrowth in NS-1 cells. Intriguingly, SQ22536 potentiated the vorinostat induced neurite
outgrowth suggesting the possible role of additional signaling pathways in neurotrophic action of
vorinostat. Stimulation of vorinostat mediated neuritogenesis may not be solely attributed to the
activation of TrkA/MAPK/PI-3K pathway and would require interrogation of additional signaling
pathways.
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Treatment of NS-1 cells with vorinostat and flow cytometric analysis showed that the drug
arrested the cells in G2M phase, as indicated by decrease in cells in S phase with concomitant
increase of cells in G2M phase. Further, vorinostat treatment resulted in hyperacetylation of
histones (H3 & H4) and α-tubulin as indicated by Western blot analysis of NS-1 cells lysates and
immunostaining of the treated cells with anti-α-tubulin antibodies.
Other pan-HDAC inhibitors namely trichostatin-A (TSA) and belinostat showed different
responses on the NS-1 cells, compared to prominent neurotrophic action of vorinostat. TSA is an
antifungal antibiotic and selective inhibitor of class I and II HDACs. Treatment of NS-1 cells with
TSA did not induce neurite outgrowth. Also, TSA treatment did not show significant effect on
neurotrophic action of NGF. Belinostat (referred as PDX101) also is a potent inhibitor of class I
and II HDACs and presently under development for treatment of hematological malignancies.
Similar to TSA, belinostat also did not induce neurite outgrowth in NS- 1 cells by itself. However
it significantly attenuated the NGF-mediated neurite outgrowth in NS-1 cells. Belinostat by itself
did not induce phosphorylation of ERK. However, there was increased phosphorylation of ERK
in NS- cells co-treated with belinostat and NGF. The increase in phosphorylation of ERK in NS1 cells treated with belinostat and NGF compared to the NS-1 cells treated with NGF alone
contrasted the observation regarding attenuation of NGF-mediated neurite outgrowth belinostat
and would required additional investigations. Treatment of NS-1 cells with belinostat induced
hyperacetylation of histones H3 and H4. However, it did not induce the hyperacetylation of αtubulin like vorinostat.
PCI-34051, a HDAC 8 inhibitor was also evaluated for potential neurotrophic action and
induction of neurite outgrowth in NS-1 cell. Treatment of NS-1 cells with PCI-34051 induced the
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neurite outgrowth. However, treatment of NS-1 cells with PCI-34051 did not produce
hyperacetylation of histones (H3 and H4) and α-tubulin. The observations indicate a differential
mechanism for neurotrophic action of PCI-34051.
Treatment of NS-1 cells with tubastatin-A, a selective HDAC6 inhibitor, produced
significant hyperacetylation of α-tubulin. However, tubastatin-A neither produced significant
effect on the neurite outgrowth alone nor it have any effect on NGF-stimulated neurite outgrowth.
Tenovin-1 a sirtunin SirT1 and SirT2 inhibitor, did not induce neurite outgrowth by itself.
However, it significantly attenuated the neurite outgrowth induced by NGF, similar to that
observed with belinostat. Tenovin did not show acetylation of histone H3/H4 in NS-1 cells.
Earlier, it has been reported to cause hyperacetylation of histone H4 and activate p53.
The results presented regarding neurotrophic action of different HDAC inhibitors indicate
multiple mechanisms of their actions. The vorinostat mediated neurotrophic response shows
involvement of conventional neurotrophin signaling pathways such as activation of extracellular
neurotrophin receptor TrkA and subsequent activation of ERK/PI-3K pathways.
Differential epigenetic status of the NS-1 cells at the time of treatment with these HDAC
inhibitors as well as expression of a select set of gene during the process of neurite out growth/
differentiation might be attributed to the varying response of the HDAC inhibitors. It may be
interesting to assess the transcription dependent/independent effects of the individual HDAC
inhibitors in NS-1 cells and monitor specific gene expression changes during the process of
differentiation of the NS-1 cells. .
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In conclusion, the results presented clearly established vorinostat to induce neurite
outgrowth in NS-1 cells.

These studies have advanced our knowledge and understanding

regarding mechanism action of vorinostat in promoting neuritogenesis and neuronal
differentiation. These studies also suggested that the HDAC inhibitor like vorinostat may be of
significant interest in the development of novel therapeutic approaches for treatment of
neurodegenerative diseases by virtue of their ability to induce neurite outgrowth and their ability
to cross blood brain barrier. Additionally these studies have also shed light on other pan and
selective HDAC inhibitors regarding their potential to induce neurite outgrowth in NS-1 cells and
also partially elucidated their mechanism for action.

108

BIBLIOGRAPHY

109

Akagi M, Matsui N, Akae H, Hirashima N, Fukuishi N, Fukuyama Y, Akagi R (2015) Nonpeptide
neurotrophic agents useful in the treatment of neurodegenerative diseases such as
Alzheimer's disease. J Pharmacol Sci. 127:155-163.
Allen SJ, Dawbarn D (2006) Clinical relevance of the neurotrophins and their receptors. Clin Sci
(Lond).110:175-191.
Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y,
Shiekhattar R, Shilatifard A, Workman J, Zhang Y(2007) “New nomenclature for
chromatin-modifying enzymes.” Cell. 131: 633-636.
Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation
prevent axonal degeneration. Science. 305:1010-1013.
Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Prospero
ND, Pellizzoni L, Fischbeck KH, Sumner CJ (2007) Trichostatin A increases SMN
expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest.
117:659-671.
Avvakumov N, Cote J (2007) The MYST family of histone acetyltransferases and their intimate
links to cancer. Oncogene. 26: 5395-5407.
Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ (2008) A novel histone
deacetylase 8 (HDAC8) -specific inhibitor PCI-34051 induces apoptosis in T-cell
lymphomas. Leukemia. 22:1026-1034.
Balasubramanian S, Verner E, and Buggy JJ (2009) Isoform-specific histone deacetylase
inhibitors: the next step? Cancer Lett. 280: 211-221.
Balasubramaniyan V,Boddeke E, Bakels R, Küst B, Kooistra S, Veneman A,Copray S (2006)
Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse
neural stem cells. Neuroscience. 143:939-951.
Banker G, Goslin K (1998) Types of nerve cell cultures, their advantages and limitation in: G.
Banker, K Goslin (Eds.), Culturing nerve cells, 2nd edition, MIT press, Massachusetts, pp.
11-35.
Bannister AJ & Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res.
21: 381-395.
Biermann J, Boyle J, Pielen A, Lagrèze WA (2011) Histone deacetylase inhibitors sodium
butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells.
Mol Vis. 5:395-403.
Bjerling P, Silverstein RA, Thon G, Caudy A, Grewal S and Ekwall K (2002) Functional
divergence between histone deacetylases in fission yeast by distinct cellular localization
and in vivo specificity. Mol. Cell. Biol. 22:170-2181.
Bose P, Dai Y, and Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action:
Emerging insights. Pharmacol Ther 143:323-336
110

Brinton RD, Yamazaki R, Gonzalez CM, O’Neill K, Schreiber SS (1998) Vasopressin induction
of the immediate early gene, NGFI-A, in cultured hippocampal glial cells. Brain Res.Mol.
Brain Res. 57:73–85.
Burns A, Iliffe S (2009) Alzheimer's disease. BMJ (Clinical research ed.).338: b158.
PMID 19196745.
Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP (2010) Rational design and
simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am
Chem Soc. 132:10842-10846.
Butler R, Bates GP (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine
disorders. Nat Rev Neurosci. 7:784-96.
Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf
B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ,
Dangond F (2005) Transcriptional therapy with the histone deacetylase inhibitor
Trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol.
164:10–21.
Chen M-C, Lin H, Hsu F-N, Huang P-H, Lee G-S, Wang PS (2010) Involvement of cAMP in
nerve growth factor-triggered p35/Cdk5 activation and differentiation in PC12 cells. Am J
Physiol Cell Physiol .299: C516-C527.
Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM,
and Hong JS (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia
cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry
.11:1116-1125.
Chen SH, Wu HM, Ossola B, Schendzielorz N, Wilson BC, Chu CH, Chen SL, Wang Q, Zhang
D, Qian L, X Li, Hong JS, Lu RB (2012). Suberoylanilide hydroxamic acid, a histone
deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br
J Pharmacol. 165: 494-505.
Choudhary C, Kumar C, Gnad F, Nielsen ML ,Rehman M, C T, Walther, J V, Olsen, Matthias M
(2009) Lysine Acetylation targets protein complexes and co-regulates major cellular
functions. Science. 325:834-840.
Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT (2009) Multiple roles of HDAC inhibition
in neurodegenerative conditions. Trends Neurosci. 32: 591-601.
Craig AM, Banker G (1994) Neuronal polarity. Annul Rev Neurosci. 17: 267-310.
da Silva JS, and Dotti CG (2002) Breaking the neuronal sphere: regulation of the actin cytoskeleton
in neuritogenesis. Nat Rev Neurosci. 3:694-704.
Dash PK, Orsi SA, Moore AN (2009) Histone deacetylase inhibition combined with behavioral
therapy enhances learning and memory following traumatic brain injury. Neuroscience.
163:1-8.
111

de Oliveira RM, Pais TF, Outeiro TF (2010) Sirtuins: common targets in aging and in
neurodegeneration. Curr Drug Targets.11:1270-1280.
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone
deacetylases (HDACs): characterization of the classical HDAC family. Biochem J.
370:737-749.
Deepali K, Ritesh KS, Sandeep CC, Mary EB, Levy K,Craig AE, and Mohammad Athara (2013)
Vorinostat an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by
dampening mTOR signaling pathway in a human xenograft murine model . Toxico and
Applied Pharmacol. 266: 233-244.
Dijkmans TF, van Hooijdonk LW, Schouten TG, Kamphorst JT, Vellinga AC, Meerman JH,
Fitzsimons CP, de Kloet ER, Vreugdenhil E (2008) Temporal and functional dynamics of
transcriptome during nerve growth factor induced differentiation. J Neurochem. 105:23882403.
Dokmanovic M, Clarke C, Marks PA (2007). Histone Deacetylase Inhibitors: Overview and
Perspectives. Mol Cancer Res 5:981-989.
Dompierre JP, Godin JD, Charrin BC, Cordelières FP, King SJ, Humbert S, Saudou F(2007)
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's
disease by increasing tubulin acetylation. J Neurosci. 27:3571-3583.
Donmez G (2012) The neurobiology of sirtuins and their role in neurodegeneration. Trends
Pharmacol Sci. 33:494-501.
Dotti CG, Sullivan CA, and Banker GA (1988) The establishment of polarity by hippocampal
neurons in culture. J Neurosci 8:1454-1468.
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development
of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:
495-528.
Emery AC, Eiden MV, Eiden LE (2014) Separate cyclic AMP sensors for neuritogenesis, growth
arrest, and survival of neuroendocrine cells. Biol Chem. 289:10126-10139.
Enarsson M, Erlandsson A, Larsson H, and Forsberg-Nilsson, K (2002) Extracellular SignalRegulated Protein Kinase Signaling Is Uncoupled From Initial Differentiation of Central
Nervous System Stem Cells to Neurons. Mol Cancer Res.1 : 147-154.
Enciu AM, Nicolescu MI, Manole CG, Muresanu DF, Popescu LM, Popescu BO (2011)
Neuroregeneration in neurodegenerative disorders. BMC Neurol. 11: 75.
Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR,
Luthi-Carter R, Hersch SM(2003) Histone deacetylase inhibition by sodium butyrate
chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
J Neurosci. 23:9418-9427.
Filbin MT (2000) Axon regeneration: Vaccinating against spinal cord injury. Curr. Biol. 10:R100R103.
112

Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP
(1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA
inhibitors. Nature. 401: 188-193.
Fournier AE, Strittmatter, SM (2001) Repulsive factors and axon regeneration in the CNS.Curr.
Opin. Neurobiol.11: 89-94.
Frumm SM, Fan ZP, Ross KN, Duvall JR ,Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF,
Smith WB et al (2013) Selective HDAC1/HDAC2 inhibitors induce neuroblastoma
differentiation. Chem. Biol. 20: 713-715.
Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S,Nishimura S (1995)
Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and
morphological transformation of NIH3T3 cells.Oncogene.10:1119-1123.
Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF(2004) Neuroprotective effects
of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 5:235–241.
Gasser T (2001).Genetics of Parkinson's disease. J. Neurol.248:833-840.
Gaub P, Tedeschi A, Puttagunta R, Nguyen T, Schmandke A, Di Giovanni (2010) HDAC
inhibition promotes neuronal outgrowth and counteracts growth cone collapse through
CBP/p300 and P/CAF-dependent p53 acetylation. Cell Death Differ 17: 1392-1408.
Giordano G, Costa LG (2011) Primary neurons in culture and neuronal cell lines for in vitro
neurotoxicological studies. Methods Mol Biol.758:13-27.
Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone
proteins. Gene. 363:15-23.
Grant S, Easley C, and Kirkpatrick P (2007) Vorinostat. Nat Rev Drug Discov 6:21-22.
Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM (2008)
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism
involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J
Neurosci.28:11500-11510.
Green LA, and Tischler A(1982) PC 12 pheochromocytoma cells in neurobiological research. Adv
Cell Neurobiol .3:373-414.
Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E (2009) Characterization of the
action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends
Pharmacol Sci. 30: 55–60.
Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in
development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10:3242.
Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL(2003) Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc
Natl Acad Sci USA. 100: 4389-4394.
113

Hansen M, Gimsing P, Rasmussen A, Jensen PB, Knudsen LM (2005) A Phase I Study of the
Histone Deacetylase (HDAC) Inhibitor PXD101 in Patients with Advanced Hematological
Tumors (abstract). J Clin Oncology. ASCO Annual Meeting Proceedings, 16S:3137.
Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, Gould TD, Manji HK, Chen G (2004) Mood
stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and
neurogenesis. J Neurosci. 24: 6590-2599.
Hasan MR, Kim JH, Kim YJ, Kwon KJ, Shin CY, Kim HY, HanSH, Choi DH, Lee J (2013) Effect
of HDAC inhibitors on neuro-protection and neurite outgrowth in primary rat cortical
neurons following ischemic insult. Neurochem Res. 38:1921-1930.
Hashioka S, Klegeris A, McGeer PL (2012) The histone deacetylase inhibitor suberoylanilide
hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-gamma.
J. Neuroinflamm. 9:113.
Her S, Lee MS, Morita K (2010) Trichostatin A stimulates steroid 5alpha-reductase gene
expression in rat C6 glioma cells via a mechanism involving Sp1 and Sp3 transcription
factors. J Mol Neurosci 41:252-262.
Herskovits AZ, Guarente L (2014) SIRT1 in neurodevelopment and brain senescence.Neuron.
81:471-83.
Hildmann C, Riester D, and Schwienhorst A (2007) Histone deacetylases--an important class of
cellular regulators with a variety of functions. Appl Microbiol Biotechnol 75:487-497.
Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, Sato M, Horio Y (2008)
Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation.
Proc. Natl. Acad. Sci. USA. 105:15599-15604.
Hochedlinger K, and Plath K (2009) Epigenetic reprogramming and induced pluripotency.
Development. 136:509-523.
Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S,
Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates
GP (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates
motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S
A.100:2041-6.
Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH (2004) Histone deacetylase inhibitionmediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl
Acad Sci USA. 101:16659-16664.
Huang EJ, & Reichardt LF (2003) Trk receptors: Roles in neuronal signal transduction. Ann
Review of Biochem. 72:609-642.
Huangfu D, Maehr R, Guo W, Eijkelenboom A ,Snitow M, Chen AE & DA Melton (2008)
Induction of pluripotent stem cells by defined factors is greatly improved by smallmolecule compounds. Nat Biotechnol. 26:795-797.
114

Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang X-F & Yao
T-P (2002) HDAC6 is a microtubule-associated deacetylase. Nature. 417:455-458.
Husstege MM, Muggironi M, Liu A, Casaccia-Bonnefil P (2002) Histone Deacetylase Activity Is
Necessary for Oligodendrocyte Lineage Progression. Jour of Neurosci. 22:10333-1034.
Itoh Y, Suzuki T, Miyata N (2008) Isoform-selective histone deacetylase inhibitors. Curr Pharm
Des.14:529-544.
Jenny YS, Hsiuyi T, Lian Xu ,Zachary H, Bryan C, Mariateresa F, Bangmin Z, Kaveh M,Guang
Y,Ping G, Yangsheng Z,Xia L ,Nikhil C. Munshi,CJ. Patterson, SP, and Treon (2011)
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and
extracellular signal regulated kinase pathways leading to apoptosis in Waldenström
macroglobulinemia cells. Leuk Lymphoma. 52:1777-1786.
Jeonga S-G, Ohnb T, Kimc, SH, Choa G-W (2013) Valproic acid promotes neuronal
differentiation by induction of neuroprogenitors in human bone-marrow mesenchymal
stromal cells. Neurosci lett. 554: 22-27.
Jones LL , Oudega M , Bunge MB ,Tuszynski MH (2001) Neurotrophic factors, cellular bridges
and gene therapy for spinal cord injury. J Physiol. 533:83–89.
Jung, GA, Yoon JY, Moon BS, Yang DH, Kim HY, Lee SH, Bryja V, Arenas E and Choi KY
(2008) Valproic acid induces differentiation and inhibition of proliferation in neural
progenitor cells via the beta-catenin-Ras-ERK-p21 Cip/WAF 1 pathway. BMC Cell Biol.
9:1471-2121.
Kandel ER (2001) The molecular biology of memory storage: a dialogue between genes and
synapses. Science 294: 1030-1038.
Kao CY, Hsu YC, Liu JW, Lee DC, Chung YF, , Chiu IM (2013) The mood stabilizer valproate
activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities. J
Neurochem. 126: 4-18.
Kaplan DR and Miller FD (1997) Signal transduction by neurotrophin receptors. Curr. Opin. Cell
Biol. 9: 213 - 221.
Kazantsev AG, Thompson LM (2008) Therapeutic application of histone deacetylase inhibitors
for central nervous system disorders. Nat. Rev. Drug Discov. 7: 854-868.
Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC,
Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS,
Sehested M (2008) Determination of the class and isoform selectivity of small-molecule
histone deacetylase inhibitors. Biochem J. 409:581-589.
Kim HJ, Leeds P, Chuang DM (2009) The HDAC inhibitor, sodium butyrate, stimulates
neurogenesis in the ischemic brain. J Neurochem. 110:1226-1240.
Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone deacetylase inhibitors
exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model
of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 321: 892-901.
115

Kim S-J, Lee B-H, Lee Y-S, Kanga K-S (2007) Defective cholesterol traffic and neuronal
differentiation in neural stem cells of Niemann–Pick type C disease improved by valproic
acid, a histone deacetylase inhibitor. Biochem Biophys Res Commun.. 360: 593-599.
Kiryushko D, Berezin, V, Bock E (2004) Regulators of neurite outgrowth: Role of cell adhesion
molecules. Ann NY Acad. Sci. 1014: 140-154.
Kontopoulos E, Parvin JD and Feany MB (2006) α-synuclein acts in the nucleus to inhibit histone
acetylation and promote neurotoxicity. Hum Mol Genet. 15:3012-3023.
Koppel I, Timmusk T (2013) Differential regulation of Bdnf expression in cortical neurons by
class-selective histone deacetylase inhibitors. Neuropharmacology. 75: 106-115.
Kostrouchova M, Kostrouch Z, Kostrouchova M (2007) Valproic acid, a molecular lead to
multiple regulatory pathways. Folia Biologica (Praha). 53:37-49.
Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J.
19:1176-1179.
Kouzarides T (2007) Chromatin modifications and their function. Cell. 128: 693-705.
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB,
Yao TP(2005) HDAC6 regulates HSP90 acetylating and chaperone dependent activation
of glucocorticoid receptor. Mol Cell. 18:601-607.
Kretsovali A, Hadjimichael C, Charmpilas N (2012) Histone deacetylase inhibitors in cell
pluripotency,
differentiation,
and
reprogramming.
Stem
Cells
Int.
doi:10.1155/2012/184154.
Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in
adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov
Devel. 9:580-586.
Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V,
Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J,
Lane DP, Westwood NJ (2008) Discovery, in vivo activity, and mechanism of action of a
small-molecule p53 activator. Cancer Cell. 13:454-463.
Laura S, Rodrigo , Wollenhaupt de AB, Bianca P, Samira SV, Carolina G, Camila LF, Morgana
M, Keila MC, Márcia KSA, João Q, & Flavio K (2014) Histone deacetylase activity and
brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania.
Revista Brasileira de Psiquiatria. 36:39-46.
Lebel EA, Boukamp P, and Tafrov ST, (2010) “Irradiation with heavy-ion particles changes the
cellular distribution of human histone acetyltransferase HAT1.” Mol Cell Biochem.
339:271-284.
Lemoine M, and Younes A (2010) Histone deacetylase inhibitors in the treatment of lymphoma.
Discov Med 10:462-470.
Li P, Matsunaga K, Yamakuni T Ohizumi Y (2002) Picrosides I and II, selective enhancers of the
116

mitogen-activated protein kinase-dependent signaling pathway in the action of
neuritogenic substances on PC12D cells. Life Sci 71:1821-1835.
Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ (2008) HDAC6 is required for epidermal
growth factor- induced beta-catenin nuclear localization. J Biol Chem 283:12686-12690.
Liscum L, Klansek JJ. Niemann-Pick disease type C (1998) Curr Opin Lipido. 9:131-135.
Liu DJ, Hammer D, Komlos D, Chen KY, Firestein BL, Liu AY (2014) SIRT1 knockdown
promotes neural differentiation and attenuates the heat shock response. J Cell Physiol.
229:1224-35.
Liu H, Wu H, Wang Y, Wang Y, Wu X, Ju S, Wang X (2012) Inhibition of class II histone
deacetylase blocks proliferation and promotes neuronal differentiation of the embryonic
rat neural progenitor cells. Acta Neurobiol Exp (Wars) .72:365-76.
Longo FM, and Massa SM (2013) Small-molecule modulation of neurotrophin receptors: a
strategy for the treatment of neurological disease. Nat Rev Drug Discov 12:507-525.
Lu J, Frerich JM, Turtzo LC, Li S Chiang J Yang C, Wang X , Zhang C, Wu C, Sun Z, Niu G,
Zhuang Z, Brady RO, Chen X (2013) Histone deacetylase inhibitors are neuroprotective
and preserve NGF- mediated cell survival following traumatic brain injury. Proc Natl Acad
Sci U S A. 110:10747-10752.
MacDonald JL, Roskams AJ (2008) Histone deacetylases 1 and 2 are expressed at distinct stages
of neuro-glial development. Dev Dyn. 237:2256–2267.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller, T and Kelly, WK (2001) Histone
deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 1:194-202.
Marks PA (2010 The clinical development of histone deacetylase inhibitors as targeted anticancer
drugs. Expert Opin. Investig.. Drugs 19:1049-1066.
Marks PA and Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell
Biochem. 107:600-608.
Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as
anticancer agents. Expert Opin Investig Drugs 14: 1497-1511.
Marshall CJ (1998) Signal transduction.Taking the Rap. Nature. 392: 553-554.
Maruoka H, Sasaya H, Sugihara K, Shimoke, and Ikeuchi T (2011) Low-molecular-weight
compounds having neurotrophic activity in cultured PC12 cells and neurons. J Bio Chem.
150: 473-475.
McAllister AK (2001) Neurotrophins and neuronal differentiation in the central nervous system.
Cell Mol Life Sci.58:1054–1060.
McKerracher L (2001) Spinal cord repair: Strategies to promote axon regeneration. Neurobiol.
Dis.8:11-18.

117

Michan S and D Sinclair (2007) Sirtuins in mammals: insights into their biological function.
Biochem J. 404: 1-13.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama
M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks
PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in
multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540545.
Moodie SA, Willumsen BM, Weber MJ, and Wolfman A (1993) Complexes of Ras.GTP with Raf1 and mitogen-activated protein kinase kinase. Science. 260: 1658-1661.
More SV, Koppula S, Kim IS, Kumar H, Kim BW, and Choi DK (2012). The role of bioactive
compounds on the promotion of neurite outgrowth. Molecules 17:6728-6753
Munno, DW, Woodin, MA, Lukowiak, K, Syed, NI, and Dickinson, PS (2000) Different extrinsic
trophic factors regulate neurite outgrowth and synapse formation between identified
Lymnaea neurons. J. Neurobiol. 44:20-30.
Nakagawa S , Kim JE, Lee R, Malberg, JE., Chen, J, Steffen, C, Zhang, YJ, Nestler, EJ, Duman,
RS (2002) Regulation of neurogenesis in adult mouse hippocampus by cAMP and the
cAMP response element-binding protein. J. Neurosci. 22:3673-3682.
Nakamura T, Aoki K, and Matsuda M (2008) FRET imaging and in silico simulation: analysis of
the signaling network of nerve growth factor-induced neuritogenesis. Brain Cell Biol.
36:19-30.
Neuwald AF and Landsman D (1997) GCN5-related histone N-acetyltransferases belong to a
diverse superfamily that includes the yeast SPT10 protein. Trends Biochem Sci. 22:154155.
Nör C,Sassi FA Farias CBde ,Schwartsmann G,Abujamra AL,Lenz G, Brunetto AL, Roesle R The
Histone Deacetylase Inhibitor Sodium Butyrate PromotesCell Death and Differentiation
and Reduces Neurosphere Formation in Human Medulloblastoma Cells (2013). Mol
Neurobiol. 48:533-543
North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003). The human Sir2 ortholog, SIRT2,
is an NAD+-dependent tubulin deacetylase. Mol Cell. 11:437-444.
Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F, Dhe-Paganon S, Arrowsmith
CH, Zhai RG (2012) Protein aggregates are recruited to aggresome by histone deacetylase
6 via unanchored ubiquitin C termini. J Biol Chem. 287:2317-2327.
Parthun MR (2007) Hat1: the emerging cellular roles of a type B histone acetyltransferase.
Oncogene . 26:5319-5328.
Patapoutian A, Reichardt LF (2001) Trk receptors: mediators of neurotrophin action. Curr Opin
Neurobiol.11 (3):272-80.

118

Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS (2005) Valproate
pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat
primary midbrain cultures: role of microglia. Brain Res Mol Brain Res. 134:162-169.
Pesavento E, Capsoni S, Domenici L, Cattaneo A (2002) Acute cholinergic rescue of
synapticPlasticity in the neurodegenerating cortex of anti-nerve-growth-factor mice. Eur.
J. Neurosci. 15: 1030–1036.
Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF (2006) Additive
neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a
transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 22:40-49.
Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown
R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts
by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2:721-728.
Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS,
Jeffers M (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian
cancer studies. Mol Cancer Ther. 5:2086-2095.
Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W,
Wang K, Song W (2008) Valproic acid inhibits Abeta production, neuritic plaque
formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med.
205:2781-2789.
Rakhit S, Pyne S, and Pyne, NJ (2001) Nerve growth factor stimulation of p42/p44 mitogenactivated protein kinase in PC12 cells: role of G(i/o), G protein-coupled receptor kinase 2,
beta-arrestin I, and endocytic processing. Mol Pharmacol. 60: 63-70.
Rasheed WK, Johnstone RW, Prince HM (2007) Histone deacetylase inhibitors in cancer therapy.
Expert Opin Investig Drugs 16:659-78.
Ravni A, Vaudry D, Gerdin MJ, Eiden MV, Falluel-Morel A, Gonzalez BJ, Vaudry H, Eiden LE
(2008) A cAMP-dependent, protein kinase A-independent signaling pathway mediating
neuritogenesis through Egr1 in PC12 cells. Mol Pharmacol. 73:1688-708.
Ricobaraza A, C-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A (2009)
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's
disease mouse model. Neuropsychopharmacology. 34:1721-1732.
Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y,
Blumcke I, Hahnen E, Wirth B (2010) SAHA Ameliorates the SMA phenotype in two
mouse models for spinal muscular atrophy. Hum. Mol. Genet. 19: 1492-1506.
Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A,
Kozikowski AP , Jaffrey SR, Twiss JL, Ratan RR , Langley B (2009). HDAC6 is a target
for protection and regeneration following injury in the nervous system. Proc. Natl. Acad.
Sci. U.S.A. 106: 19599-19604.

119

Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J,
O'Regan JP, Deng HX,et al.(1993) Mutations in Cu/Zn superoxide dismutase are
associated with familial amyotrophic lateral sclerosis. Nature. 362: 59-62.
Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Ann rev Biochem. 70: 81-120.
Rouaux C, Panteleeva I, René F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L, Menger
Y, Boutillier AL, Loeffler JP (2007) Sodium valproate exerts neuroprotective effects in
vivo through CREB-binding protein-dependent mechanisms but does not improve survival
in an amyotrophic lateral sclerosis mouse model. J Neurosci. 27:5535-5545.
Rowland L and Shneider N (2001) Amyotrophic lateral sclerosis. N. Engl. J. Med.344:1688-1700.
Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz
ME, Brown RH Jr (2005) Sodium phenylbutyrate prolongs survival and regulates
expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J
Neurochem.93:1087-1098.
Sadoul K, Wang J, Diagouraga B, Khochbin S (2011) The tale of protein lysine acetylation in the
cytoplasm. J. Biomed. Biotechnol. p 970382. doi:10.1155/2011/970382.
Saha RN, Pahan K (2006) HATs and HDACs in neurodegeneration: a tale of disconcerted
acetylation homeostasis. Cell Death Differ.13:539-550.
Schinder AF and Poo M (2000)The neurotrophin hypothesis for synaptic plasticity. Trends
Neurosci. 23: 639-645.
Schroeder FA, Lin CL, Crusio WE, Akbarian S (2007) Antidepressant-like effects of the histone
deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry. 62:55-64.
Schwechter BR, Millet LE, Levin LA (2007) Histone deacetylase inhibition-mediated
differentiation of RGC-5 cells and interaction with survival. Invest Ophthalmol Vis Sci.
48:2845-2857.
Shimoke K, Fukunaga K, Matsumura Y, Kudo M, and Ikeuchi T (2009) Protection from ER
stress-mediated apoptosis by the neurotrophins. Curr Topics in Biochem Res. 11: 19-28.
Siebzehnrubl FA, Buslei R, Eyupoglu IY, Seufert S, Hahnen E, and Blumcke I (2007) Histone
deacetylase inhibitors increase neuronal differentiation in adult forebrain precursor cells.
Exp Brain Res. 176: 672-678.
Slingerland M, Guchelaar HJ, and Gelderblom H (2014) Histone deacetylase inhibitors: an
overview of the clinical studies in solid tumors. Anticancer Drugs 25:140-149.
Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E,
Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson
LM
(2001) Histone deacetylase inhibitors arrest polyglutamine-dependent
neurodegeneration in Drossophila. Nature. 413:739-743.
Sterner DE, and Berger SL (2000) Acetylation of histones and transcription-related factors.
Microbiol. Mol. Biol. Rev. 64: 435-459.
120

Sugino T, Maruyama M, Tanno M, Kuno A, Houkin K, Horio Y (2010) Protein deacetylase SIRT1
in the cytoplasm promotes nerve growth factor-induced neurite outgrowth in PC12 cells.
FEBS Lett. 584:2821-2826.
Sun G, Fu C, Shen C, Shi Y (2011) Histone Deacetylases in Neural Stem Cells and Induced
Pluripotent Stem Cells. J Biomed Biotechnol Article ID 835968 doi:10.1155/2011/835968.
Sun G, Yu RT, Evans RM, Shi Y (2007) Orphan nuclear receptor TLX recruits histone
deacetylases to repress transcription and regulate neural stem cell proliferation. Proc Natl
Acad Sci U S A. 104:15282-15287.
Takano M, Horie H, Iijima Y, Dezawa M, Sawada H, and Ishikawa Y (2002) Brain-derived
neurotrophic factor enhances neurite regeneration from retinal ganglion cells in aged
human retina in vitro. Exp. Eye Res. 74: 319-323.
Takase K, Oda S, Kuroda M, Funato H (2013) Monoaminergic and neuropeptidergic neurons
have distinct expression profiles of histone deacetylases. PLoS One. 8(3):e58473. doi:
10.1371/journal.pone.0058473.
Tang G, Wong JC, Zhang W, Wang Z, Zhang N, Peng Z, Zhang Z, Rong Y, Li S, Zhang M, Yu
L, Feng T, Zhang X, Wu X, Wu JZ, Chen L (2014).Identification of a novel aminotetralin
class of HDAC6 and HDAC8 selective inhibitors. J Med Chem. 57:8026-34.
Temple S (2001) Stem cell plasticity-building the brain of our dreams. Nat Rev Neurosci. 2:513520.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM
(1998) Embryonic stem cell lines derived from human blastocysts. Science. 282:11451147.
Tomioka T, Maruoka H, Kawa H, Yamazoe R, Fujiki D, Shimoke K, Ikeuchi T (2014) The histone
deacetylase inhibitor trichostatin A induces neurite outgrowth in PC12 cells via the
epigenetically regulated expression of the nur77 gene. Neurosci Res. 88: 39-48.
Trapp J, Meier , Hongwiset D, Kassack MU, Sippl W, Jung M(2007) Structure-activity studies on
suramin analogues as inhibitors of NAD+-dependent of NAD+-dependent histone
deacetylases(sirtuins). Chem Med Chem .2: 119-143.
Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB,
Sehested M, Ritchie JW (2007) The histone deacetylase inhibitor PXD101 synergises with
5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother
Pharmacol. 60:275-83.
Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P,Reinberg D(2004) . Human SirT1
interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell
16: 93-105.
Vaudry D, Stork PJ, Lazarovici P and Eiden LE (2002) Signaling pathways for PC12 cell
differentiation: making the right connections. Science 29: 1648-1649.
121

Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, Attner MA, Cabrera SM, McDonough
CB, Brindle PK, Abel T and Wood MA (2007) Histone deacetylase inhibitors enhance
memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation.
Neurosci. 27:6128-6140.
Wang Y, Wu X, Zhong Y, Shen J, Wu X, Ju S, Wang X (2014) Effects of histone deacetylase
inhibition on the survival, proliferation and migration of Schwann cells, as well as on the
expression of neurotrophic factors and genes associated with myelination .Int Jour of Mol
med. 34:599-605.
Wang Y, Wang X, Liu L (2009) HDAC inhibitor trichostatin A-inhibited survival of dopaminergic
neuronal cells. Neurosci Lett. 467: 212-216.
Westerink RHS, Ewing AG (2008) The PC12 cell as model for neurosecretion. Acta Physiologica.
192: 273-285.
Wiech NL, Fisher JF, Helquist P, Wiest O (2009) Inhibition of histone deacetylases: a
pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem.
9:257-271.
Wu JI, Lessard J, Olave IA, Qiu Z, Ghosh A, Graef IA, Crabtree GR (2007) Regulation of
dendritic development by neuron-specific chromatin remodeling complexes. Neuron. 56:
94-108.
Wu X, Li S, Wu Q, Peng Y, Yu D, Wang H, Chui D, Zhao J (2013) Histone deacetylase inhibition
leads to neuroprotection through regulation on glial function Molecular
Neurodegeneration. 8(Suppl 1):49-(last page).
Xu K, Dai XL, Huang HC, Jiang ZF (2011) Targeting HDACs: a promising therapy for
Alzheimer's disease. Oxid. Med. Cell. Longev. 143269. doi: 10.1155/2011/143269.
Xu WS, Parmigiani RB and Marks PA (2007) Histone deacetylase inhibitors: molecular
mechanisms of action.Oncogene. 26: 5541-5552.
Yamaguchi M, Tonou-Fujimori N, Komori A, Maeda2 R, Nojima Y , Li H, Okamoto H, Masai
I (2003) Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing
Wnt and Notch signaling pathways mediated tubulin deacetylation. Proc Natl Acad Sci U
S A. 100: 4389-4394.
Yang XJ and Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast
to mice and men. Nat Rev Mol Cell Biol. 9:206-218.
Yang X-J, and Seto E (2008) Lysine acetylation: codified crosstalk with other posttranslational
modifications. Mol Cell. 31: 449-461.
Yang YC, Chen CN, Wu CI, Huang WJ, Kuo TY, Kuan MC, Tsai TH, Huang JS, Huang CY
(2013) NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of
Histone Deacetylase and Enhances Learning and Memory in Rats. Evid Based Complement
Alternat Med. 514908. doi: 10.1155/2013/514908.
122

Yoshida M, Horinouchi S and Beppu T (1995) Trichostatin A and trapoxin: Novel chemical probes
for the role of histone acetylation in chromatin structure and function. BioEssays. 17:423430.
Yu CW, Chang PT, Hsin LW, Chern JW (2013) Quinazolin-4-one derivatives as selective histone
deacetylase-6 inhibitors for the treatment of Alzheimer's disease. J Med Chem. 56:67756791.
Yu IT, Park JY, Kim SH, Lee JS, Kim YS, Son H (2009) Valproic acid promotes neuronal
differentiation by induction of proneural factors in association with H4 acetylation.
Neuropharmacology. 56:473-480.
Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001) The mood stabilizer
valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J
Biol Chem. 276:31674-31683.
Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang
XJ, Dent SR, Yao TP, Lane WS, Seto E (2007) HDAC 6 modulates cell motility by altering
the acetylation level of cortactin. Mol Cell. 27: 197-213.
Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P (2003) HDAC-6 interacts
with and deacetylates tubulin and microtubules in vivo. EMBO J. 22:1168-1179.
Zhang ZZ, Gong YY, Shi YH, Zhang W, Qin XH, Wu XW (2012) Valproate promotes survival
of retinal ganglion cells in a rat model of optic nerve crush. Neuroscience. 224:282-9310.
Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L , Zeng Y, Li H , Li Y, Shi J, An
W, M S, Hancock, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y, Guan K-L (2010)
Regulation of Cellular Metabolism by Protein Lysine Acetylation. Science.327:1000-1004.
Zhou Q, Dalgard CL, Wynder C, Doughty ML (2011) Histone deacetylase inhibitors SAHA and
sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult
subventricular cells. BMC Neurosci. 12:50 doi: 10.1186/1471-2202-12-50.

123

VITA
Surabhi Shukla

Education
Ph.D.

Pharmaceutical Sciences (Pharmacology) to be awarded
Aug 2015
University of Mississippi, University, MS, USA.

MS (2004 – 2006)

Biotechnology
Sardar Patel University, Vallabh Vidyanagar, Gujarat, India

BS (2001 – 2004)

Biotechnology
Sardar Patel University, Vallabh Vidyanagar, Gujarat, India

Research Experience:
Graduate Research Assistant

Division of Pharmacology, (2010 – Present)
University of Mississippi, Oxford, MS, USA.

Senior Research Fellow

Immunology Dept. (2007 –2008)
Central Institute of Freshwater Aquaculture, Bhubaneshwar,
India.

MS Thesis Project

Division of Virology (2005 - 2006)
Defense Research Development
Gwalior, India

Intern

and

Establishment,

National Dairy Development Board (May 2005)
Anand, Gujarat, India

Membership and Awards
1. Best Poster award International conference on Science of Botanicals (ICSB), Oxford, MS,
USA (2013).
2. Sec. Best Poster award International conference on Science of Botanicals (ICSB), Oxford,
MS, USA (2015).
3. Society for Neuroscience Member (2013-Present).
124

4. Rho –Chi Society member an academic Honor Society in Pharmacy (2013-present).
5. Graduate student travel award for attending American Society for Cell Biology meeting,
Graduate School, University of Mississippi (2012).
6. Senior Research Fellow CIFA, Department of Biotechnology, India.
Publications:
1. Surabhi Shukla, Larry A Walker and Babu Lal Tekwani (2015) Vorinostat, A pan Histone
Deacetylase Inhibitor, Stimulates Neurite outgrowth in PC12 cells via activation of MAPK and
PI3K Signal Transduction Pathways. Communicated.
2. Narayan Das Chaurasiya, Surabhi Shukla, Larry Walker and Babu Lal Tekwani (2015) In vitro
assay for neuritogenesis in PC12 Cells. Communicated.
3. S.K. Nayak, P. Swain, P.K. Nanda, S. Dash, S.Shukla, P.K Meher, N.K Maiti. (2008) Effect of
endotoxin on immunity of Indian major carp, Labeo rohita. Fish and Shelfish Immunology. (24)
394-399

Teaching Experience:
Teaching Assistant

Biochemical Foundation of Therapeutics sections 1
(Fall 2012-2013)
Department of Pharmacology, University of Mississippi

Assistant Lecturer

Department of Biotechnology, (2006- 2007)
IASE Deemed University, Mancheswar, Bhubaneshwar,
India
Teaching and conducting practical classes of B.Tech
Biotechnology and M.Sc Biotechnology. Taught
Biochemistry, plant biotechnology, microbiology and
virology.

125

